@NP	Ensheathing Cells and Methylprednisolone	1
@NP	Axonal Regeneration and Functional Recovery	50
@NP	the Lesioned Adult Rat Spinal Cord Holly H.	97
@NP	Nash ,1 Rosemary C.	142
@NP	Nash ,1	142
@NP	Rosemary C.	149
@NP	Borke ,1,2 and Juanita J.	161
@NP	Borke ,1,2	161
@NP	Juanita J.	175
@NP	Anders1 ,2	186
@NP	1Neuroscience Program and 2Department of Anatomy , Physiology , and Genetics	196
@NP	1Neuroscience Program and 2Department	196
@NP	Anatomy , Physiology , and Genetics	237
@NP	F.	272
@NP	Edward	275
@NP	He '	282
@NP	bert School of Medicine , Uniformed Services University	286
@NP	bert School	286
@NP	Medicine , Uniformed Services University	301
@NP	the Health Sciences	344
@NP	Bethesda , Maryland 20814-4799	365
@NP	Axons	396
@NP	spinal cord injury -LRB- SCI -RRB- in adult mammals	427
@NP	spinal cord injury -LRB- SCI -RRB-	427
@NP	spinal cord injury	427
@NP	SCI	447
@NP	adult mammals	455
@NP	permanent loss	481
@NP	function	499
@NP	SCI	515
@NP	ensheathing cells -LRB- ECs -RRB-	520
@NP	ensheathing cells	520
@NP	ECs	539
@NP	recovery in animal models	552
@NP	recovery	552
@NP	animal models	564
@NP	methylprednisolone -LRB- MP -RRB-	587
@NP	methylprednisolone	587
@NP	MP	607
@NP	neurological recovery in humans	620
@NP	neurological recovery	620
@NP	humans	645
@NP	this study	656
@NP	the effectiveness of combining ECs and MP after SCI	668
@NP	the effectiveness	668
@NP	ECs and MP	699
@NP	SCI	716
@NP	the first time	741
@NP	the corticospinal tract	773
@NP	adult rats	800
@NP	ECs	812
@NP	the lesion	839
@NP	MP	855
@NP	24 hr	879
@NP	6 weeks after injury	889
@NP	6 weeks	889
@NP	injury	903
@NP	functional recovery	911
@NP	successful performance	957
@NP	directed forepaw reaching -LRB- DFR -RRB- , expressed as percentages	983
@NP	directed forepaw	983
@NP	-LRB- DFR -RRB- , expressed as percentages	1009
@NP	-LRB- DFR -RRB-	1009
@NP	percentages	1029
@NP	Axonal regeneration	1042
@NP	the number of corticospinal axons	1087
@NP	the number	1087
@NP	corticospinal axons	1101
@NP	biotin dextran tetramethylrhodamine	1149
@NP	caudal to the lesion	1186
@NP	caudal	1186
@NP	the lesion	1196
@NP	control rats	1217
@NP	either no treatment or vehicle	1241
@NP	no treatment	1248
@NP	vehicle	1264
@NP	abortive axonal regrowth -LRB- 1 mm -RRB-	1277
@NP	abortive axonal regrowth	1277
@NP	1 mm	1303
@NP	poor DFR success -LRB- 38 and 42 % , respectively -RRB-	1313
@NP	poor DFR success	1313
@NP	38 and 42 % , respectively	1331
@NP	38 and 42 %	1331
@NP	38	1331
@NP	42 %	1338
@NP	controls	1372
@NP	MP-treated rats	1382
@NP	significantly more axons 7 mm caudal to the lesion	1402
@NP	significantly more axons	1402
@NP	7 mm caudal to the lesion	1427
@NP	7 mm caudal	1427
@NP	the lesion	1442
@NP	DFR performance	1458
@NP	57 %	1502
@NP	Rats that received ECs in combination with MP	1508
@NP	Rats	1508
@NP	ECs	1527
@NP	combination	1534
@NP	MP	1551
@NP	significantly more axons	1558
@NP	all other lesioned rats	1588
@NP	13 mm	1618
@NP	Successful DFR performance	1625
@NP	rats with EC transplants , both without -LRB- 72 % -RRB-	1680
@NP	rats with EC transplants , both without	1680
@NP	rats with EC transplants	1680
@NP	rats	1680
@NP	EC transplants	1690
@NP	72 %	1720
@NP	-LRB- 78 % -RRB- MP	1734
@NP	78 %	1735
@NP	other lesioned rats	1758
@NP	These data	1779
@NP	previous reports	1798
@NP	ECs	1820
@NP	axonal regeneration and functional recovery	1832
@NP	regeneration	1839
@NP	spinal cord lesions	1882
@NP	addition	1906
@NP	this research	1916
@NP	evidence	1939
@NP	combination	1967
@NP	MP and ECs	1980
@NP	axonal regrowth	1999
@NP	13 mm caudal	2021
@NP	the lesion at 6 weeks after injury	2037
@NP	the lesion	2037
@NP	6 weeks after injury	2051
@NP	6 weeks	2051
@NP	injury	2065
@NP	Key words	2073
@NP	Key	2073
@NP	words	2077
@NP	animal ; axotomy ; corticospinal tract ; behavioral analysis	2084
@NP	animal	2084
@NP	axotomy ; corticospinal tract	2092
@NP	axotomy	2092
@NP	corticospinal tract	2101
@NP	behavioral analysis	2122
@NP	cells	2152
@NP	fluorescent tracers	2159
@NP	forelimb function	2180
@NP	glia	2199
@NP	neuronal regeneration	2205
@NP	olfactory bulb	2228
@NP	recovery of function	2244
@NP	recovery	2244
@NP	function	2256
@NP	spinal cord injury	2266
@NP	Sprague Dawley rats Unlike axons	2286
@NP	Sprague Dawley rats	2286
@NP	axons	2315
@NP	the peripheral nervous system -LRB- PNS -RRB-	2324
@NP	the peripheral nervous system	2324
@NP	PNS	2355
@NP	Fawcett and Keynes , 1990 ; Raivich and Kreutzberg , 1993	2396
@NP	Fawcett and Keynes	2396
@NP	1990 ; Raivich and Kreutzberg	2416
@NP	1990	2416
@NP	Raivich and Kreutzberg	2422
@NP	1993	2446
@NP	injured CNS axons	2453
@NP	Schwab and Bartholdi , 1996 ; Nicholls et al. , 1999	2491
@NP	Schwab and Bartholdi	2491
@NP	1996 ; Nicholls et al.	2513
@NP	1996	2513
@NP	Nicholls et al.	2519
@NP	Nicholls	2519
@NP	et al.	2528
@NP	1999	2536
@NP	The one exception	2543
@NP	the olfactory system	2573
@NP	Olfactory neurons	2595
@NP	a life span of 4 weeks	2618
@NP	a life span	2618
@NP	4 weeks	2633
@NP	Graziadei and Monti-Graziadei	2642
@NP	1978	2673
@NP	they	2685
@NP	new neurons	2695
@NP	neuroepithelial precursors	2724
@NP	the olfactory epithelium -LRB- Graziadei and Monti - Graziadei , 1978 -RRB-	2762
@NP	the olfactory epithelium	2762
@NP	Graziadei and Monti	2788
@NP	Graziadei , 1978	2809
@NP	Graziadei	2809
@NP	1978	2820
@NP	the olfactory bulb	2851
@NP	functional synapses -LRB- Kosaka et al. , 1998 -RRB-	2879
@NP	functional synapses	2879
@NP	Kosaka	2900
@NP	et al. , 1998	2907
@NP	et al.	2907
@NP	1998	2915
@NP	Fascicles of olfactory axons	2922
@NP	Fascicles	2922
@NP	olfactory axons	2935
@NP	the PNS -LRB- Doucette , 1991 -RRB-	2977
@NP	the PNS	2977
@NP	Doucette , 1991	2986
@NP	Doucette	2986
@NP	1991	2996
@NP	the CNS -LRB- Doucette , 1993 -RRB-	3011
@NP	the CNS	3011
@NP	Doucette , 1993	3020
@NP	Doucette	3020
@NP	1993	3030
@NP	a glial cell	3039
@NP	olfactory ensheathing cells -LRB- ECs -RRB- -LRB- Doucette , 1984 -RRB-	3059
@NP	olfactory ensheathing cells -LRB- ECs -RRB-	3059
@NP	olfactory ensheathing cells	3059
@NP	ECs	3088
@NP	Doucette	3094
@NP	1984	3104
@NP	their unique ability to promote regeneration in the olfactory system	3120
@NP	regeneration	3152
@NP	the olfactory system	3168
@NP	researchers	3190
@NP	transplanted ECs	3207
@NP	spinal cord injury -LRB- SCI -RRB-	3230
@NP	spinal cord injury	3230
@NP	SCI	3250
@NP	ECs	3276
@NP	their ability to promote regeneration	3289
@NP	regeneration	3314
@NP	injection of EC suspensions at the site of a dorsal rhizotomy in rats	3334
@NP	injection	3334
@NP	EC suspensions at the site of a dorsal rhizotomy in rats	3347
@NP	EC suspensions	3347
@NP	the site of a dorsal rhizotomy in rats	3365
@NP	the site	3365
@NP	a dorsal rhizotomy in rats	3377
@NP	a dorsal rhizotomy	3377
@NP	rats	3399
@NP	regenerating axons	3405
@NP	the spinal cord gray matter -LRB- Ramon-Cueto and Nieto-Sampedro , 1994 -RRB-	3436
@NP	the spinal cord gray matter	3436
@NP	Ramon-Cueto and Nieto-Sampedro , 1994	3465
@NP	Ramon-Cueto and Nieto-Sampedro	3465
@NP	1994	3497
@NP	ECs	3504
@NP	spinal cord	3526
@NP	electrolytic destruction of the corticospinal tract	3544
@NP	electrolytic destruction	3544
@NP	the corticospinal tract	3572
@NP	CST	3597
@NP	the growth of CST axons	3614
@NP	the growth	3614
@NP	CST axons	3628
@NP	the transplant	3646
@NP	the host CST and restoration	3666
@NP	directed forepaw	3698
@NP	-LRB- DFR -RRB- , a measure of function -LRB- Li et al. , 1997 -RRB-	3724
@NP	-LRB- DFR -RRB-	3724
@NP	a measure of function -LRB- Li et al. , 1997 -RRB-	3731
@NP	a measure	3731
@NP	function -LRB- Li et al. , 1997 -RRB-	3744
@NP	function	3744
@NP	Li	3754
@NP	et al. , 1997	3757
@NP	et al.	3757
@NP	1997	3765
@NP	a subsequent study using the same experimental model	3775
@NP	a subsequent study	3775
@NP	the same experimental model	3800
@NP	regenerating CST axons	3829
@NP	parallel bundles	3866
@NP	the lesioned area	3896
@NP	the spinal cord	3928
@NP	transplantation of ECs	3950
@NP	transplantation	3950
@NP	ECs	3969
@NP	the injury site	3978
@NP	Li	3995
@NP	et al. , 1998	3998
@NP	et al.	3998
@NP	1998	4006
@NP	Schwann	4019
@NP	cell-filled guidance channels	4027
@NP	injections of ECs	4071
@NP	injections	4071
@NP	ECs	4085
@NP	spinal cords	4101
@NP	propriospinal axons	4136
@NP	2.5 cm -LRB- Ramon - Cueto et al. , 1998 -RRB-	4173
@NP	2.5 cm	4173
@NP	Ramon	4181
@NP	Cueto et al. , 1998	4188
@NP	Cueto	4188
@NP	et al.	4194
@NP	1998	4202
@NP	ECs	4219
@NP	axonal regeneration	4245
@NP	abilities in rats	4286
@NP	abilities	4286
@NP	rats	4299
@NP	complete spinal cord transection -LRB- Ramon-Cueto et al. , 2000 -RRB-	4310
@NP	complete spinal cord transection	4310
@NP	Ramon-Cueto	4344
@NP	et al. , 2000	4356
@NP	et al.	4356
@NP	2000	4364
@NP	ECs	4382
@NP	a valuable tool	4404
@NP	spinal cord regeneration	4433
@NP	Bartolomei and Greer	4459
@NP	Bartolomei	4459
@NP	Greer	4474
@NP	2000 ; Franklin and Barnett , 2000 ; Raisman , 2001 ; Treloar et al. , 2001	4481
@NP	2000	4481
@NP	Franklin and Barnett , 2000 ; Raisman , 2001 ; Treloar et al. , 2001	4487
@NP	Franklin and Barnett , 2000	4487
@NP	Franklin and Barnett	4487
@NP	2000	4509
@NP	Raisman , 2001	4515
@NP	Raisman	4515
@NP	2001	4524
@NP	Treloar et al. , 2001	4530
@NP	Treloar	4530
@NP	et al. , 2001	4538
@NP	et al.	4538
@NP	2001	4546
@NP	A common treatment for SCI in human beings	4553
@NP	A common treatment	4553
@NP	SCI in human beings	4576
@NP	SCI	4576
@NP	human beings	4583
@NP	administration of methylprednisolone -LRB- MP -RRB-	4599
@NP	administration	4599
@NP	methylprednisolone -LRB- MP -RRB-	4617
@NP	methylprednisolone	4617
@NP	MP	4637
@NP	a synthetic glucocorticoid steroid	4642
@NP	its enhanced anti-inflammatory activity	4701
@NP	mineralocorticoid activity	4754
@NP	cortisol , the prototypical glucocorticoid	4793
@NP	cortisol	4793
@NP	the prototypical glucocorticoid	4803
@NP	Hall , 1992	4836
@NP	Hall	4836
@NP	1992	4842
@NP	The extreme lipophilicity of MP , a drawback to its intravenous use ,	4849
@NP	The extreme lipophilicity of MP	4849
@NP	The extreme lipophilicity	4849
@NP	MP	4878
@NP	a drawback to its intravenous use	4882
@NP	a drawback	4882
@NP	its intravenous use	4896
@NP	the production of an MP-hemisuccinated ester -LRB- Solu-Medrol -RRB-	4938
@NP	the production	4938
@NP	an MP-hemisuccinated ester -LRB- Solu-Medrol -RRB-	4956
@NP	an MP-hemisuccinated ester	4956
@NP	Solu-Medrol	4984
@NP	Solu-Medrol	5003
@NP	the body	5032
@NP	the ester	5042
@NP	the pro-drug	5070
@NP	the free steroid	5094
@NP	the blood -- brain barrier -LRB- Hall , 1992 -RRB-	5137
@NP	the blood	5137
@NP	brain barrier -LRB- Hall , 1992 -RRB-	5147
@NP	brain barrier	5147
@NP	Hall , 1992	5162
@NP	Hall	5162
@NP	1992	5168
@NP	many therapies	5731
@NP	regeneration	5757
@NP	SCI	5776
@NP	it	5816
@NP	any single therapy	5840
@NP	all of the problems associated with the lack of regeneration after SCI	5870
@NP	all	5870
@NP	the problems associated with the lack of regeneration after SCI	5877
@NP	the problems	5877
@NP	the lack of regeneration	5906
@NP	the lack	5906
@NP	regeneration	5918
@NP	SCI	5937
@NP	Two therapies shown to promote repair after SCI when used alone	5942
@NP	Two therapies	5942
@NP	repair	5973
@NP	SCI	5986
@NP	ECs andMP	6010
@NP	we	6032
@NP	the effects of combining MP administration with EC transplantation	6044
@NP	the effects	6044
@NP	MP administration	6069
@NP	EC transplantation	6092
@NP	regeneration of the CST	6114
@NP	regeneration	6114
@NP	the CST	6130
@NP	injury	6144
@NP	we	6157
@NP	this combination of treatments	6172
@NP	this combination	6172
@NP	treatments	6192
@NP	longdistance regrowth of CST axons and functional recovery	6212
@NP	longdistance regrowth	6212
@NP	CST axons and functional recovery	6237
@NP	axons	6241
@NP	acute cervical SCI in the adult rat	6277
@NP	acute cervical SCI	6277
@NP	the adult rat	6299
@NP	MATERIALS AND METHODS Subjects Eighty-one adult Sprague Dawley rats	6315
@NP	MATERIALS	6315
@NP	METHODS Subjects Eighty-one adult Sprague Dawley rats	6329
@NP	METHODS Subjects	6329
@NP	Eighty-one adult Sprague Dawley rats	6346
@NP	300	6384
@NP	400 gm ; Taconic Farms , Germantown , NY	6388
@NP	400 gm	6388
@NP	Taconic Farms , Germantown , NY	6396
@NP	Taconic Farms	6396
@NP	Germantown , NY	6411
@NP	this study	6440
@NP	Twenty rats	6452
@NP	use to harvest ECs for transplants	6469
@NP	ECs for transplants	6484
@NP	ECs	6484
@NP	transplants	6492
@NP	61 rats	6509
@NP	control and experimental groups	6543
@NP	those 61 rats	6579
@NP	17	6594
@NP	the study	6618
@NP	they	6643
@NP	14 d	6671
@NP	surgery -LRB- n = 15 -RRB-	6682
@NP	surgery	6682
@NP	n	6691
@NP	15	6695
@NP	they	6702
@NP	response	6726
@NP	a food reward	6738
@NP	surgery -LRB- n = 2 -RRB-	6759
@NP	surgery	6759
@NP	n	6768
@NP	2	6772
@NP	Surgeries Cultures ECs	6776
@NP	Surgeries Cultures	6776
@NP	ECs	6795
@NP	a previously described technique -LRB- Nash et al. , 2001 -RRB-	6837
@NP	a previously described technique	6837
@NP	Nash	6871
@NP	et al. , 2001	6876
@NP	et al.	6876
@NP	2001	6884
@NP	the rats	6900
@NP	the nasal and frontal bones	6948
@NP	Olfactory nerve rootlets and olfactory bulbs	6990
@NP	Olfactory nerve rootlets	6990
@NP	olfactory bulbs	7019
@NP	The rootlets and outer two layers of the olfactory bulb	7050
@NP	The rootlets	7050
@NP	outer two layers of the olfactory bulb	7067
@NP	outer two layers	7067
@NP	the olfactory bulb	7087
@NP	the cells	7167
@NP	media	7195
@NP	a suspension containing 8.5 x 10 5 cells/ml	7220
@NP	a suspension	7220
@NP	8.5 x 10 5 cells/ml	7244
@NP	8.5	7244
@NP	10 5 cells/ml	7250
@NP	10 5	7250
@NP	cells/ml	7255
@NP	The cell suspension	7265
@NP	an uncoated flask	7301
@NP	48 hr , 37 °C and 5 % CO2	7334
@NP	48 hr	7334
@NP	37 °C	7341
@NP	5 % CO2	7350
@NP	purification	7362
@NP	this 48 hr period	7383
@NP	all other cell types in the cell suspension	7402
@NP	all other cell types	7402
@NP	the cell suspension	7426
@NP	the uncoated plastic flask	7458
@NP	the ECs	7494
@NP	the supernatant	7514
@NP	this , our previously described purification process	7537
@NP	this	7537
@NP	our previously described purification process	7543
@NP	Nash	7590
@NP	et al. , 2001	7595
@NP	et al.	7595
@NP	2001	7603
@NP	the ECs	7610
@NP	≈ 93 % pure	7639
@NP	purification	7662
@NP	the ECs	7676
@NP	Cell Tracker green	7718
@NP	Cell Tracker	7718
@NP	50 µM ; Molecular Probes	7738
@NP	50 µM	7738
@NP	Molecular Probes	7745
@NP	Eugene , OR	7763
@NP	Eugene	7763
@NP	OR	7771
@NP	immediate transplantation	7779
@NP	Surgical procedures Rats	7806
@NP	control or experimental groups	7857
@NP	experimental groups	7868
@NP	The three control groups	7889
@NP	sham -LRB- n = 5 -RRB-	7931
@NP	sham	7931
@NP	n	7937
@NP	5	7941
@NP	lesion -LRB- n = 5 -RRB-	7945
@NP	lesion	7945
@NP	n	7953
@NP	5	7957
@NP	vehicle -LRB- n = 5 -RRB-	7965
@NP	vehicle	7965
@NP	n	7974
@NP	5	7978
@NP	The three experimental groups	7982
@NP	MP -LRB- n = 10 -RRB- , EC -LRB- n = 9 -RRB- , and MP/EC -LRB- n = 10 -RRB-	8029
@NP	MP -LRB- n = 10 -RRB-	8029
@NP	MP	8029
@NP	n	8033
@NP	10	8037
@NP	EC -LRB- n = 9 -RRB-	8042
@NP	EC	8042
@NP	n	8046
@NP	9	8050
@NP	MP/EC -LRB- n = 10 -RRB-	8058
@NP	MP/EC	8058
@NP	n	8065
@NP	10	8069
@NP	anesthesia	8080
@NP	isoflurane -LRB- 5 % ; Abbott Laboratories , North Chicago , IL -RRB-	8096
@NP	isoflurane	8096
@NP	5 % ; Abbott Laboratories	8108
@NP	5 %	8108
@NP	Abbott Laboratories	8112
@NP	North Chicago , IL	8133
@NP	North Chicago	8133
@NP	IL	8148
@NP	application of ophthalmic ointment -LRB- E.	8156
@NP	application	8156
@NP	ophthalmic ointment -LRB- E.	8171
@NP	ophthalmic ointment	8171
@NP	E.	8192
@NP	Fougera & Co. , Melville , NY -RRB- ,	8195
@NP	Fougera & Co.	8195
@NP	Melville	8210
@NP	NY	8220
@NP	the rats	8225
@NP	an operating board in such a way	8249
@NP	an operating board	8249
@NP	such a way	8271
@NP	the cervical spinal cord	8293
@NP	maximum exposure	8322
@NP	A laminectomy	8340
@NP	the dorsum of the spinal cord between C2 and C4	8377
@NP	the dorsum	8377
@NP	the spinal cord between C2 and C4	8391
@NP	the spinal cord	8391
@NP	C2 and C4	8415
@NP	The dorsal columns	8426
@NP	all rats except for those in the sham group	8482
@NP	all rats	8482
@NP	those in the sham group	8502
@NP	those	8502
@NP	the sham group	8511
@NP	a suture needle	8527
@NP	the spinal cord	8562
@NP	the dorsal funiculus	8589
@NP	The suture thread	8611
@NP	a pair of iridectomy scissors	8652
@NP	a pair	8652
@NP	iridectomy scissors	8662
@NP	the dorsal funiculus	8715
@NP	the dorsal CST	8757
@NP	Visualization of the dorsal horns and the central gray commissure	8773
@NP	Visualization	8773
@NP	the dorsal horns and the central gray commissure	8790
@NP	the dorsal horns	8790
@NP	the central gray commissure	8811
@NP	accuracy of the lesion borders	8849
@NP	accuracy	8849
@NP	the lesion borders	8861
@NP	ECs	8881
@NP	Cell	8901
@NP	Tracker green	8906
@NP	10 µl Hamilton syringe	8935
@NP	10 µl	8935
@NP	Hamilton syringe	8941
@NP	the cut surfaces	8964
@NP	the CST	8984
@NP	two injections in the rostral surface and two in the caudal surface	8993
@NP	two injections in the rostral surface	8993
@NP	two injections	8993
@NP	the rostral surface	9011
@NP	two in the caudal surface	9035
@NP	two	9035
@NP	the caudal surface	9042
@NP	The injections	9063
@NP	the cut surface of the spinal cord	9099
@NP	the cut surface	9099
@NP	the spinal cord	9118
@NP	each injection	9139
@NP	≈ 500 µm lateral	9158
@NP	the posterior median septum and ≈ 500 µm dorsal	9177
@NP	the posterior median septum	9177
@NP	≈ 500 µm dorsal	9209
@NP	the central gray matter	9227
@NP	Each injection site	9252
@NP	0.5 µl	9281
@NP	a suspension	9291
@NP	50,000 ECs in DMEM -LRB- Biofluids , Rockville , MD -RRB-	9315
@NP	50,000 ECs	9315
@NP	DMEM -LRB- Biofluids , Rockville , MD -RRB-	9329
@NP	DMEM	9329
@NP	Biofluids	9335
@NP	Rockville	9346
@NP	MD	9357
@NP	injections	9366
@NP	≈ 2 min	9414
@NP	Rats receiving the vehicle for ECs	9422
@NP	Rats	9422
@NP	the vehicle for ECs	9437
@NP	the vehicle	9437
@NP	ECs	9453
@NP	an equal volume of DMEM	9476
@NP	an equal volume	9476
@NP	DMEM	9495
@NP	the CST	9505
@NP	A pledget of biodegradable Gelfoam	9514
@NP	A pledget	9514
@NP	biodegradable Gelfoam	9527
@NP	Fluorogold -LRB- 3 % in 0.9 % saline ; Molecular Probes -RRB-	9559
@NP	Fluorogold	9559
@NP	3 % in 0.9 % saline ; Molecular Probes	9571
@NP	3 %	9571
@NP	0.9 % saline ; Molecular Probes	9577
@NP	0.9 % saline	9577
@NP	Molecular Probes	9590
@NP	the lesion site -LRB- see Tracers below -RRB-	9622
@NP	the lesion site	9622
@NP	Tracers	9643
@NP	The overlying muscles and skin	9659
@NP	the rats	9708
@NP	a heating pad	9732
@NP	body temperature	9758
@NP	Each rat	9776
@NP	a single dose	9794
@NP	buprenorphine	9811
@NP	0.1 mg/kg ; Reckitt & Colman Pharmaceuticals	9826
@NP	0.1 mg/kg	9826
@NP	Reckitt & Colman Pharmaceuticals	9837
@NP	Richmond , VA	9871
@NP	Richmond	9871
@NP	VA	9881
@NP	surgery	9903
@NP	pain	9924
@NP	One hour after the spinal cord	9930
@NP	One hour	9930
@NP	the spinal cord	9945
@NP	a bolus injection	9975
@NP	MP sodium succinate	9996
@NP	Solu-Medrol , 30 mg/kg ; Pharmacia Upjohn , Kalamazoo , MI	10017
@NP	Solu-Medrol	10017
@NP	30 mg/kg ; Pharmacia Upjohn	10030
@NP	30 mg/kg	10030
@NP	Pharmacia Upjohn	10040
@NP	Kalamazoo , MI	10058
@NP	0.9 % saline	10076
@NP	a tail vein	10109
@NP	This injection	10122
@NP	four subsequent administrations of MP	10153
@NP	four subsequent administrations	10153
@NP	MP	10188
@NP	a tail vein -LRB- 30 mg/kg -RRB- at 6 hr intervals	10196
@NP	a tail vein -LRB- 30 mg/kg -RRB-	10196
@NP	a tail vein	10196
@NP	30 mg/kg	10209
@NP	6 hr intervals	10222
@NP	Rats receiving vehicle for MP	10238
@NP	Rats	10238
@NP	vehicle for MP	10253
@NP	vehicle	10253
@NP	MP	10265
@NP	the same treatment regimen	10278
@NP	an equal volume of 0.09 % saline in a tail vein	10328
@NP	an equal volume	10328
@NP	0.09 % saline in a tail vein	10347
@NP	0.09 % saline	10347
@NP	a tail vein	10363
@NP	all lesioned rats	10380
@NP	their bladders	10399
@NP	surgery and three times per day	10456
@NP	surgery	10456
@NP	three times per day	10468
@NP	three times	10468
@NP	day	10484
@NP	spontaneous urination	10494
@NP	Tracers During surgery -LRB- see Surgical procedures -RRB-	10526
@NP	Tracers	10526
@NP	surgery	10541
@NP	Surgical procedures	10554
@NP	a fluorescent retrograde tracer , Fluorogold	10576
@NP	a fluorescent retrograde tracer	10576
@NP	Fluorogold	10609
@NP	the neurons whose axons were transected	10650
@NP	the neurons	10650
@NP	axons	10668
@NP	the lesion	10702
@NP	Seven weeks	10714
@NP	injury	10732
@NP	rats	10740
@NP	injection	10763
@NP	biotin dextran tetramethylrhodamine -LRB- BDT ; Molecular Probes -RRB-	10776
@NP	biotin dextran tetramethylrhodamine	10776
@NP	BDT ; Molecular Probes	10813
@NP	BDT	10813
@NP	Molecular Probes	10818
@NP	This fluorescent anterograde tracer , injected into the primary motor cortex ,	10837
@NP	This fluorescent anterograde tracer	10837
@NP	the primary motor cortex	10888
@NP	CST axons	10932
@NP	the lesion site in the spinal cord	10952
@NP	the lesion site	10952
@NP	the spinal cord	10971
@NP	anesthesia with isoflurane -LRB- 5 % -RRB-	10994
@NP	anesthesia	10994
@NP	isoflurane -LRB- 5 % -RRB-	11010
@NP	isoflurane	11010
@NP	5 %	11022
@NP	rats	11027
@NP	a stereotaxic instrument	11047
@NP	a total of six stereotaxically determined holes -LRB- 0.9 mm diameter -RRB-	11077
@NP	a total	11077
@NP	six	11088
@NP	holes -LRB- 0.9 mm diameter -RRB-	11119
@NP	holes	11119
@NP	0.9 mm diameter	11126
@NP	the skull over the primary motor cortices associated with the forelimbs	11159
@NP	the skull	11159
@NP	the primary motor cortices associated with the forelimbs	11174
@NP	the primary motor cortices	11174
@NP	the forelimbs	11217
@NP	The anteroposterior -LRB- AP -RRB- and mediolateral -LRB- ML -RRB-	11232
@NP	The anteroposterior -LRB- AP -RRB-	11232
@NP	The anteroposterior	11232
@NP	AP	11253
@NP	mediolateral -LRB- ML -RRB-	11261
@NP	mediolateral	11261
@NP	ML	11275
@NP	these injections , from bregma ,	11295
@NP	these injections	11295
@NP	bregma	11318
@NP	+0.5 AP and ± 3.5 ML ; +1.5 A/P and ± 2.5 ML ; and +2.5 AP and ±	11343
@NP	+0.5 AP and ± 3.5 ML	11343
@NP	+0.5 AP	11343
@NP	± 3.5 ML	11355
@NP	+1.5 A/P and ± 2.5 ML	11364
@NP	+1.5 A/P	11364
@NP	± 2.5 ML	11377
@NP	+2.5 AP and ±	11390
@NP	+2.5 AP	11390
@NP	±	11402
@NP	1.5 ML	11403
@NP	All injections	11411
@NP	a depth of 2.5 mm	11444
@NP	a depth	11444
@NP	2.5 mm	11455
@NP	the surface of the skull	11467
@NP	the surface	11467
@NP	the skull	11482
@NP	A 10 µl Hamilton syringe	11493
@NP	BDT	11537
@NP	layer V of the cortex	11558
@NP	layer V	11558
@NP	the cortex	11569
@NP	Three injections into each cortical hemisphere	11581
@NP	Three injections	11581
@NP	each cortical hemisphere	11603
@NP	a total of 1.2 µl of the anterograde tracer	11652
@NP	a total	11652
@NP	1.2 µl of the anterograde tracer	11663
@NP	1.2 µl	11663
@NP	the anterograde tracer	11673
@NP	Bone wax -LRB- Ethicon , Somerville , NJ -RRB-	11697
@NP	Bone wax	11697
@NP	Ethicon	11707
@NP	Somerville	11716
@NP	NJ	11728
@NP	the holes	11749
@NP	the skull	11762
@NP	the scalp	11773
@NP	a single dose of buprenorphine -LRB- 0.1 mg/kg -RRB-	11800
@NP	a single dose	11800
@NP	buprenorphine -LRB- 0.1 mg/kg -RRB-	11817
@NP	buprenorphine	11817
@NP	0.1 mg/kg	11832
@NP	surgery	11878
@NP	pain	11899
@NP	Rats	11905
@NP	3 d	11922
@NP	tracer injections	11932
@NP	Functional testing Apparatus A	11951
@NP	version of an apparatus -LRB- Castro , 1972 -RRB- designed to test DFR	11991
@NP	version	11991
@NP	an apparatus -LRB- Castro , 1972 -RRB- designed to test DFR	12002
@NP	an apparatus	12002
@NP	Castro	12016
@NP	1972	12024
@NP	DFR	12047
@NP	ability -LRB- Fig. 1A , B -RRB-	12080
@NP	ability	12080
@NP	Fig. 1A , B	12089
@NP	Fig. 1A	12089
@NP	B	12097
@NP	The apparatus	12101
@NP	a box with two compartments separated by a Plexiglas divider	12119
@NP	a box	12119
@NP	two compartments separated by a Plexiglas divider	12130
@NP	two compartments	12130
@NP	a Plexiglas divider	12160
@NP	The two compartments	12181
@NP	a main compartment -LRB- 30.5 x 6.25 x 5 inches -RRB-	12212
@NP	a main compartment	12212
@NP	30.5	12232
@NP	x 6.25 x 5 inches	12237
@NP	6.25	12239
@NP	5 inches	12246
@NP	the rat and a minor compartment	12260
@NP	the rat	12260
@NP	a minor compartment	12272
@NP	30.5	12293
@NP	x 3.5 x 3 inches	12298
@NP	3.5	12300
@NP	3 inches	12306
@NP	the food reward	12320
@NP	14 adjacent slots of equal size -LRB- 2 x 1.25 x 3 inches -RRB-	12363
@NP	14 adjacent slots	12363
@NP	equal size -LRB- 2 x 1.25 x 3 inches -RRB-	12384
@NP	equal size	12384
@NP	2	12396
@NP	x 1.25 x 3 inches	12398
@NP	1.25	12400
@NP	3 inches	12407
@NP	The floor of the minor compartment	12418
@NP	The floor	12418
@NP	the minor compartment	12431
@NP	a movable shelf	12465
@NP	The shelf	12482
@NP	a 0.75 inch opening in the floor between the compartments	12527
@NP	a 0.75 inch opening	12527
@NP	the floor between the compartments	12550
@NP	the floor	12550
@NP	the compartments	12568
@NP	Testing procedures	12613
@NP	a continuous floor between the two compartments	12644
@NP	a continuous floor	12644
@NP	the two compartments	12671
@NP	All presurgical and postsurgical testing	12693
@NP	the three-quarter inch opening in the floor	12753
@NP	the three-quarter inch opening	12753
@NP	the floor	12787
@NP	The Plexiglas divider -LRB- 30.75 x 0.25 x 5 inches -RRB-	12798
@NP	The Plexiglas divider	12798
@NP	30.75	12821
@NP	x 0.25 x 5 inches	12827
@NP	0.25	12829
@NP	5 inches	12836
@NP	the rat compartment	12857
@NP	the food compartment	12882
@NP	14 semicircular holes	12907
@NP	the bottom	12942
@NP	each	12954
@NP	0.50 inches in diameter A	12972
@NP	0.50 inches	12972
@NP	diameter A	12987
@NP	190 mg food pellet -LRB- Bio-Serv , Frenchtown , NJ -RRB-	13005
@NP	190 mg food pellet	13005
@NP	Bio-Serv	13025
@NP	Frenchtown	13035
@NP	NJ	13047
@NP	each of the 14 slots	13067
@NP	each	13067
@NP	the 14 slots	13075
@NP	the minor compartment	13091
@NP	The rats	13114
@NP	a forelimb	13147
@NP	the holes in the Plexiglas divider	13166
@NP	the holes	13166
@NP	the Plexiglas divider	13179
@NP	a food pellet	13210
@NP	The rats	13225
@NP	the food pellet	13272
@NP	the holes in the Plexiglas divider	13293
@NP	the holes	13293
@NP	the Plexiglas divider	13306
@NP	one limb at a time	13360
@NP	one limb	13360
@NP	a time	13372
@NP	The opening in the floor	13380
@NP	The opening	13380
@NP	the floor	13395
@NP	the rats	13418
@NP	the food	13446
@NP	pellet	13455
@NP	it	13474
@NP	a rat	13481
@NP	a pellet	13514
@NP	the slot	13530
@NP	it	13568
@NP	the pellet	13572
@NP	the opening in the floor	13616
@NP	the opening	13616
@NP	the floor	13631
@NP	procedures	13650
@NP	surger y.	13668
@NP	Rats	13678
@NP	food restricted	13688
@NP	≈ 3 gm food/100 gm body weight per day	13715
@NP	≈ 3 gm food/100 gm body weight	13715
@NP	≈ 3 gm food/100 gm body	13715
@NP	day	13749
@NP	training and testing	13776
@NP	Weight	13798
@NP	rats	13834
@NP	no less than 80 % of heir original body weight	13855
@NP	no less than 80 %	13855
@NP	heir original body weight	13875
@NP	any time	13904
@NP	All rats	13914
@NP	shaping	13934
@NP	periods for 2	13942
@NP	periods	13942
@NP	2	13954
@NP	3 d	13956
@NP	them	13980
@NP	the task	13994
@NP	they	14009
@NP	the testing situation	14035
@NP	these shaping periods	14065
@NP	the Plexiglas divider	14088
@NP	1 inch	14131
@NP	the floor	14144
@NP	0.25 inches	14171
@NP	flush	14204
@NP	the floor	14218
@NP	all rats	14229
@NP	this most stringent level	14265
@NP	It	14292
@NP	rats	14322
@NP	a paw preference	14335
@NP	unilateral lesioning	14380
@NP	the neurons or axons	14404
@NP	the preferred limb	14442
@NP	Castro , 1977 ; Kartje-Tillotson and Castro , 1980	14462
@NP	Castro	14462
@NP	1977 ; Kartje-Tillotson and Castro	14470
@NP	1977	14470
@NP	Kartje-Tillotson and Castro	14476
@NP	1980	14505
@NP	our study	14515
@NP	a bilateral lesion	14535
@NP	both paws	14593
@NP	data on paw preference	14615
@NP	data	14615
@NP	paw preference	14623
@NP	Animals	14657
@NP	day for 5 d	14688
@NP	day	14688
@NP	5 d	14696
@NP	day for 5 d	14726
@NP	day	14726
@NP	5 d	14734
@NP	presurgical DFR data	14743
@NP	the testing period	14787
@NP	rats	14807
@NP	5 min	14823
@NP	the task	14841
@NP	many attempts	14878
@NP	they	14895
@NP	this time period	14914
@NP	Rats	14932
@NP	at least 95 % of their original weight	14964
@NP	at least 95 %	14964
@NP	their original weight	14980
@NP	they	15017
@NP	surgery	15053
@NP	surger y.	15068
@NP	Rats	15078
@NP	week	15106
@NP	weeks 2 -- 5	15118
@NP	weeks	15118
@NP	2 -- 5	15124
@NP	surgery	15134
@NP	Some rats	15143
@NP	they	15183
@NP	the grasping portion of the DFR task in the early postsurgical period	15209
@NP	the grasping portion	15209
@NP	the DFR task	15233
@NP	the early postsurgical period	15249
@NP	the food reward	15328
@NP	those rats	15349
@NP	the opening in the floor of the apparatus	15361
@NP	the opening	15361
@NP	the floor of the apparatus	15376
@NP	the floor	15376
@NP	the apparatus	15389
@NP	the food to be raked into the main compartment	15423
@NP	the main compartment	15449
@NP	the reaching portion of the DFR task	15485
@NP	the reaching portion	15485
@NP	the DFR task	15509
@NP	The severity of the grasping impairment	15542
@NP	The severity	15542
@NP	the grasping impairment	15558
@NP	the postsurgical period	15595
@NP	the opening in the floor	15634
@NP	the opening	15634
@NP	the floor	15649
@NP	the end of the postsurgical recovery period	15691
@NP	the end	15691
@NP	the postsurgical recovery period	15702
@NP	all rats	15736
@NP	successf ully	15758
@NP	the DFR task , to some degree ,	15780
@NP	the DFR task	15780
@NP	some degree	15797
@NP	the 0.75 inch opening	15815
@NP	the floor of the apparatus	15840
@NP	the floor	15840
@NP	the apparatus	15853
@NP	the sixth week after surgery	15875
@NP	the sixth week	15875
@NP	surgery	15896
@NP	rats	15905
@NP	day for 5 d	15932
@NP	day	15932
@NP	5 d	15940
@NP	postsurgical DFR data	15949
@NP	a blinded investigator	15989
@NP	the presurgery testing period	16028
@NP	the rats	16059
@NP	5 min	16081
@NP	the task	16099
@NP	the postsurgery testing period	16115
@NP	many attempts	16174
@NP	they	16191
@NP	this time period	16210
@NP	The data	16228
@NP	terms of total number of attempts and percentage of successf ul attempts	16255
@NP	terms	16255
@NP	total number of attempts and percentage of successf ul attempts	16264
@NP	total number	16264
@NP	attempts and percentage	16280
@NP	successf ul attempts	16307
@NP	An attempt	16329
@NP	a rat	16361
@NP	a slot	16380
@NP	the pellet	16401
@NP	it	16423
@NP	the gap in the floor	16434
@NP	the gap	16434
@NP	the floor	16445
@NP	A successf ul attempt	16456
@NP	a rat	16494
@NP	a pellet	16508
@NP	it	16525
@NP	the gap in the floor	16533
@NP	the gap	16533
@NP	the floor	16544
@NP	it	16566
@NP	the Plexiglas divider	16577
@NP	the pellet	16602
@NP	the main portion of the testing apparatus	16620
@NP	the main portion	16620
@NP	the testing apparatus	16640
@NP	This conservative method of counting	16663
@NP	This conservative method	16663
@NP	counting	16691
@NP	arbitrariness	16719
@NP	the investigator	16736
@NP	interpretation of the data	16775
@NP	interpretation	16775
@NP	the data	16793
@NP	Data	16803
@NP	the statistical software program Prism	16828
@NP	A one-way ANOVA	16868
@NP	an alpha-level of 0.05	16904
@NP	an alpha-level	16904
@NP	0.05	16922
@NP	a Bonferroni 's multiple comparison test	16940
@NP	a Bonferroni 's	16940
@NP	Data	16981
@NP	mean ± SEM percentages	17003
@NP	Histology Seven weeks and 3 d	17027
@NP	Histology Seven weeks	17027
@NP	3 d	17053
@NP	rats	17074
@NP	chloral hydrate -LRB- 10 ml/kg ; Sigma , St.	17102
@NP	chloral hydrate	17102
@NP	10 ml/kg	17119
@NP	Sigma , St.	17129
@NP	Louis , MO -RRB- and perfused transcardially with 300 ml of PBS , pH 7.4 ,	17140
@NP	Louis , MO -RRB- and perfused transcardially with 300 ml of PBS	17140
@NP	Louis , MO -RRB-	17140
@NP	Louis	17140
@NP	perfused transcardially with 300 ml of PBS	17155
@NP	perfused transcardially with 300 ml	17155
@NP	300	17184
@NP	PBS	17194
@NP	pH 7.4	17199
@NP	300 ml of 4 % paraformaldehyde in 0.1 M phosphate buffer	17219
@NP	300 ml	17219
@NP	4 % paraformaldehyde in 0.1 M phosphate buffer	17229
@NP	4 % paraformaldehyde	17229
@NP	0.1 M phosphate buffer	17252
@NP	the animals	17282
@NP	all brains and spinal cords	17307
@NP	all brains	17307
@NP	spinal cords	17322
@NP	overnight in 30 % sucrose	17359
@NP	overnight	17359
@NP	30 % sucrose	17372
@NP	a 0.1 M phosphate buffer solution	17387
@NP	The brains	17422
@NP	the spinal cords	17456
@NP	a thickness of 20 µm with a freezing microtome	17498
@NP	a thickness	17498
@NP	20 µm with a freezing microtome	17513
@NP	20 µm	17513
@NP	a freezing microtome	17524
@NP	ProbeOn -LRB- Fisher Scientific , Pittsburgh , PA -RRB-	17560
@NP	ProbeOn	17560
@NP	Fisher Scientific	17569
@NP	Pittsburgh	17588
@NP	PA	17600
@NP	coated slides	17604
@NP	Brain and spinal cord sections	17619
@NP	a Nikon -LRB- Tokyo , Japan -RRB- Labophot fluorescent microscope , and images	17670
@NP	a Nikon -LRB- Tokyo , Japan -RRB- Labophot fluorescent microscope	17670
@NP	Nikon -LRB- Tokyo , Japan -RRB- Labophot	17672
@NP	Tokyo	17679
@NP	Japan	17686
@NP	images	17730
@NP	a Sony -LRB- Tokyo , Japan -RRB-	17757
@NP	a Sony	17757
@NP	Tokyo	17765
@NP	Japan	17772
@NP	DKC 5000 Catseye digital still camera	17779
@NP	DKC 5000	17779
@NP	Catseye digital still camera	17788
@NP	Catseye	17788
@NP	digital still camera	17796
@NP	The forelimb representation of the primary motor cortex	17818
@NP	The forelimb representation	17818
@NP	the primary motor cortex	17849
@NP	the stereotaxic BDT injection sites	17898
@NP	Detection	17935
@NP	Fluorogold-labeled neurons	17948
@NP	layer V of the forelimb representation of the primary motor cortex	17978
@NP	layer V	17978
@NP	the forelimb representation of the primary motor cortex	17989
@NP	the forelimb representation	17989
@NP	the primary motor cortex	18020
@NP	lesioning of the CST	18055
@NP	lesioning	18055
@NP	the CST	18068
@NP	Fluorogold	18085
@NP	cut axons but not intact axons	18111
@NP	cut axons	18111
@NP	intact axons	18129
@NP	Axonal counts	18143
@NP	The spinal cord caudal to the lesion	18157
@NP	The spinal cord caudal	18157
@NP	the lesion	18183
@NP	the BDT-labeled axons	18212
@NP	the region of the spinal cord normally occupied	18244
@NP	the region	18244
@NP	the spinal cord normally occupied	18258
@NP	the spinal cord	18258
@NP	the dorsal CST	18295
@NP	a biomedical statistician	18346
@NP	it	18373
@NP	a 95 % confidence level and an SD of 10 axons	18402
@NP	a 95 % confidence level	18402
@NP	an SD of 10 axons	18429
@NP	an SD	18429
@NP	10 axons	18438
@NP	a sampling fraction of 1:4 sections	18448
@NP	a sampling fraction	18448
@NP	1:4 sections	18471
@NP	a precision of X ± 5.4 axons	18500
@NP	a precision	18500
@NP	X ± 5.4 axons	18515
@NP	X	18515
@NP	± 5.4 axons	18517
@NP	A random starting section to begin counts	18530
@NP	A random starting section	18530
@NP	counts	18565
@NP	a number between 1 and 4	18609
@NP	a number	18609
@NP	1 and 4	18626
@NP	each section	18639
@NP	the number of BDT-labeled axons	18653
@NP	the number	18653
@NP	BDT-labeled axons	18667
@NP	3 mm intervals	18700
@NP	the lesion	18725
@NP	1 mm distal to the injury -LRB- i.e. , 1 mm , 4 mm , 7 mm , etc. -RRB-	18747
@NP	1 mm	18747
@NP	the injury	18762
@NP	i.e. , 1 mm , 4 mm , 7 mm , etc.	18774
@NP	i.e. , 1 mm	18774
@NP	i.e.	18774
@NP	1 mm	18780
@NP	4 mm	18786
@NP	7 mm	18792
@NP	19 mm caudal	18815
@NP	the lesion site	18831
@NP	Innervation of the rat forepaw	18848
@NP	Innervation	18848
@NP	the rat forepaw	18863
@NP	T1 , a distance of 15.1 mm	18890
@NP	T1	18890
@NP	a distance of 15.1 mm	18894
@NP	a distance	18894
@NP	15.1 mm	18908
@NP	the lesion at C3	18921
@NP	the lesion	18921
@NP	C3	18935
@NP	analysis of the axons	18950
@NP	analysis	18950
@NP	the axons	18962
@NP	19 mm caudal to the lesion	18979
@NP	19 mm caudal	18979
@NP	the lesion	18995
@NP	the entire distance representing the forepaw	19019
@NP	the entire distance	19019
@NP	the forepaw	19052
@NP	each interval	19081
@NP	the total number	19096
@NP	BDT-labeled axons -LRB- left and right CST combined -RRB-	19116
@NP	BDT-labeled axons	19116
@NP	left and right CST combined	19135
@NP	left and right CST	19135
@NP	a 500 µm length -LRB- length of microscope field -RRB-	19170
@NP	a 500 µm length	19170
@NP	length of microscope field	19187
@NP	length	19187
@NP	microscope field	19197
@NP	each field counted	19231
@NP	each field	19231
@NP	the focal plane	19251
@NP	a single continuous axon	19307
@NP	it	19358
@NP	the focal plane	19378
@NP	the same field	19424
@NP	the data	19446
@NP	they	19470
@NP	the statistical software program Prism	19495
@NP	A one-way ANOVA	19535
@NP	an alpha-level of 0.05	19571
@NP	an alpha-level	19571
@NP	0.05	19589
@NP	a Bonferroni 's multiple comparison test	19607
@NP	a Bonferroni 's	19607
@NP	the data from all of the groups at each interval counted	19651
@NP	the data	19651
@NP	all of the groups at each interval counted	19665
@NP	all	19665
@NP	the groups at each interval counted	19672
@NP	the groups	19672
@NP	each interval counted	19686
@NP	each interval	19686
@NP	Data	19709
@NP	mean ± SEM number of axons	19731
@NP	mean ± SEM number	19731
@NP	axons	19752
@NP	RESULTS Figure 1 .	19760
@NP	RESULTS	19760
@NP	Figure 1	19768
@NP	DFR apparatuses and functional performance .	19778
@NP	DFR	19778
@NP	apparatuses and functional performance	19782
@NP	apparatuses	19782
@NP	functional performance	19798
@NP	A , A schematic of the DFR apparatus ,	19822
@NP	A schematic	19825
@NP	the DFR apparatus	19840
@NP	the front	19871
@NP	the opening in the floor at 0.75 inches	19887
@NP	the opening	19887
@NP	the floor at 0.75 inches	19902
@NP	the floor	19902
@NP	0.75 inches	19915
@NP	The circles	19928
@NP	food pellets used as a reward	19950
@NP	food pellets	19950
@NP	a reward	19971
@NP	B , The DFR apparatus ,	19981
@NP	B	19981
@NP	The DFR apparatus	19984
@NP	the opening in the floor at 0.75 inches , as was used for all testing procedures	20027
@NP	the opening	20027
@NP	the floor at 0.75 inches , as was used for all testing procedures	20042
@NP	the floor	20042
@NP	0.75 inches , as was used for all testing procedures	20055
@NP	0.75 inches	20055
@NP	all testing procedures	20084
@NP	C	20108
@NP	Graph	20111
@NP	the successful performance	20125
@NP	the DFR task	20155
@NP	percentages of total attempts	20182
@NP	percentages	20182
@NP	total attempts	20197
@NP	surgery	20232
@NP	inclusion in the study	20261
@NP	inclusion	20261
@NP	the study	20274
@NP	the rats in all of the groups	20285
@NP	the rats	20285
@NP	all of the groups	20297
@NP	all	20297
@NP	the groups	20304
@NP	the DFR task	20325
@NP	at least 90 %	20351
@NP	the trials	20367
@NP	D	20379
@NP	Graph	20382
@NP	DFR success	20396
@NP	each group after surgery -LRB- expressed as percentages of total attempts -RRB-	20412
@NP	each group	20412
@NP	surgery	20429
@NP	percentages of total attempts	20451
@NP	percentages	20451
@NP	total attempts	20466
@NP	The sham group -LRB- 94.86 ± 0.86 % -RRB-	20483
@NP	The sham group	20483
@NP	94.86 ± 0.86 %	20499
@NP	94.86	20499
@NP	± 0.86 %	20505
@NP	all of the other groups	20550
@NP	all	20550
@NP	the other groups	20557
@NP	There	20575
@NP	no significant difference in DFR success	20585
@NP	no significant difference	20585
@NP	DFR success	20614
@NP	the lesion -LRB- 38.38 ± 8.31 % -RRB-	20634
@NP	the lesion	20634
@NP	38.38 ± 8.31 %	20646
@NP	38.38 ±	20646
@NP	8.31 %	20654
@NP	vehicle -LRB- 42.41 ± 7.10 % -RRB- groups	20665
@NP	vehicle -LRB- 42.41 ± 7.10 % -RRB-	20665
@NP	vehicle	20665
@NP	42.41 ± 7.10 %	20674
@NP	42.41 ±	20674
@NP	7.10 %	20682
@NP	groups	20689
@NP	both	20706
@NP	the MP group -LRB- 56.66 ± 5.63 % -RRB-	20746
@NP	the MP group	20746
@NP	56.66 ± 5.63 %	20760
@NP	56.66	20760
@NP	± 5.63 %	20766
@NP	Groups	20776
@NP	ECs	20793
@NP	both alone -LRB- 71.84 ± 5.20 % -RRB-	20798
@NP	both alone	20798
@NP	71.84 ± 5.20 %	20810
@NP	71.84 ±	20810
@NP	5.20 %	20818
@NP	in combination with MP -LRB- 78.26 ± 0668 % -RRB-	20829
@NP	combination	20832
@NP	MP -LRB- 78.26 ± 0668 % -RRB-	20849
@NP	MP	20849
@NP	78.26 ± 0668 %	20853
@NP	78.26	20853
@NP	± 0668 %	20859
@NP	the DFR task significantly better	20879
@NP	the DFR task	20879
@NP	all other lesioned animals	20918
@NP	these two groups	20955
@NP	each other	21010
@NP	Figure 2 .	21023
@NP	Figure	21023
@NP	2	21030
@NP	Fluorogold-labeled CST neurons .	21033
@NP	Fluorogold-labeled CST	21033
@NP	neurons	21056
@NP	These neurons , filled with the retrograde tracer Fluorogold ,	21065
@NP	These neurons	21065
@NP	the retrograde tracer Fluorogold	21092
@NP	the origin of the corticospinal axons that were severed in the spinal cord at C3	21130
@NP	the origin	21130
@NP	the corticospinal axons that were severed in the spinal cord at C3	21144
@NP	the corticospinal axons	21144
@NP	the spinal cord at C3	21189
@NP	the spinal cord	21189
@NP	C3	21208
@NP	Fluorogold	21212
@NP	the soma , axons , and dendrites of these neurons	21243
@NP	the soma	21243
@NP	axons	21253
@NP	dendrites of these neurons	21264
@NP	dendrites	21264
@NP	these neurons	21277
@NP	Scale bar , 50 µm .	21292
@NP	Scale bar	21292
@NP	50 µm	21303
@NP	Figure 3 .	21311
@NP	Figure	21311
@NP	3	21318
@NP	Data from 1 , 10 , and 19 mm caudal to the lesion .	21321
@NP	Data	21321
@NP	1 , 10 , and 19 mm caudal	21331
@NP	1	21331
@NP	10	21334
@NP	19 mm caudal	21342
@NP	the lesion	21358
@NP	Representative photomicrographs	21370
@NP	axons from the lesion , vehicle , MP , EC , MP/EC , and sham groups	21405
@NP	axons	21405
@NP	the lesion , vehicle , MP , EC , MP/EC , and sham groups	21416
@NP	each of these three distances	21471
@NP	each	21471
@NP	these three distances	21479
@NP	the lesion	21511
@NP	Axons	21523
@NP	they	21545
@NP	BDT	21567
@NP	1 mm caudal to the lesion	21575
@NP	1 mm caudal	21575
@NP	the lesion	21590
@NP	there	21602
@NP	no significant difference	21611
@NP	mean number	21645
@NP	axons of the lesion -LRB- A ; 9.58 ± 5.53 -RRB-	21660
@NP	axons	21660
@NP	the lesion -LRB- A ; 9.58 ± 5.53 -RRB-	21669
@NP	the lesion	21669
@NP	A ; 9.58 ± 5.53	21681
@NP	A	21681
@NP	9.58 ± 5.53	21684
@NP	9.58	21684
@NP	± 5.53	21689
@NP	vehicle -LRB- D ; 10.95 ± 3.25 -RRB- groups	21701
@NP	vehicle	21701
@NP	D ; 10.95 ± 3.25	21710
@NP	D	21710
@NP	10.95 ± 3.25	21713
@NP	10.95 ±	21713
@NP	3.25	21721
@NP	groups	21727
@NP	there	21739
@NP	significantly more axons in the MP group -LRB- G ; 32.01 ± 3.41 -RRB-	21749
@NP	significantly more axons	21749
@NP	the MP group -LRB- G ; 32.01 ± 3.41 -RRB-	21777
@NP	the MP group	21777
@NP	G ; 32.01 ± 3.41	21791
@NP	G	21791
@NP	32.01 ± 3.41	21794
@NP	32.01 ±	21794
@NP	3.41	21802
@NP	The EC group -LRB- J ; 43.57 ± 3.05 -RRB-	21809
@NP	The EC group	21809
@NP	J ; 43.57 ± 3.05	21823
@NP	J	21823
@NP	43.57 ± 3.05	21826
@NP	43.57 ±	21826
@NP	3.05	21834
@NP	significantly more axons than the MP group	21844
@NP	significantly more axons	21844
@NP	the MP group	21874
@NP	the MP/EC group -LRB- M ; 55.99 ± 2.96 -RRB-	21892
@NP	the MP/EC group	21892
@NP	M ; 55.99 ± 2.96	21909
@NP	M	21909
@NP	55.99 ± 2.96	21912
@NP	55.99 ±	21912
@NP	2.96	21920
@NP	significantly more axons than all other lesioned groups	21930
@NP	significantly more axons	21930
@NP	all other lesioned groups	21960
@NP	this distance only	21990
@NP	there	22010
@NP	no significant -LRB- Figure legend continues	22019
@NP	no significant	22019
@NP	Figure legend	22035
@NP	Figure legend	22062
@NP	difference between the MP/EC and sham -LRB- P ; 59.02 ± 4.01 -RRB- groups .	22088
@NP	difference	22088
@NP	the MP/EC and sham -LRB- P ; 59.02 ± 4.01 -RRB- groups	22107
@NP	the MP/EC	22107
@NP	sham -LRB- P ; 59.02 ± 4.01 -RRB- groups	22121
@NP	sham	22121
@NP	P ; 59.02 ± 4.01	22127
@NP	P	22127
@NP	59.02 ± 4.01	22130
@NP	59.02 ±	22130
@NP	4.01	22138
@NP	groups	22144
@NP	10 mm distal to the lesion	22155
@NP	10 mm	22155
@NP	the lesion	22171
@NP	there	22183
@NP	no significant difference	22192
@NP	the lesion -LRB- B ; 0.66 ± 0.59 -RRB-	22226
@NP	the lesion	22226
@NP	B ; 0.66 ± 0.59	22238
@NP	B	22238
@NP	0.66 ± 0.59	22241
@NP	0.66	22241
@NP	± 0.59	22246
@NP	vehicle -LRB- E ; 0.73 ± 0.73 -RRB-	22255
@NP	vehicle	22255
@NP	E ; 0.73 ± 0.73	22264
@NP	E	22264
@NP	0.73 ± 0.73	22267
@NP	0.73	22267
@NP	± 0.73	22272
@NP	andMP -LRB- H ; 5.85 ± 0.91 -RRB- groups	22281
@NP	andMP	22281
@NP	H ; 5.85 ± 0.91	22288
@NP	H	22288
@NP	5.85 ± 0.91	22291
@NP	5.85 ±	22291
@NP	0.91	22298
@NP	groups	22304
@NP	All three of these groups	22312
@NP	All three	22312
@NP	these groups	22325
@NP	significantly fewer axons than the EC group	22343
@NP	significantly fewer axons	22343
@NP	the EC group	22374
@NP	K ; 12.35 ± 2.57	22388
@NP	K	22388
@NP	12.35 ± 2.57	22391
@NP	12.35	22391
@NP	± 2.57	22397
@NP	the EC group	22410
@NP	significantly fewer axons than the MP/EC group -LRB- N ; 22.48 ± 6.00 -RRB-	22427
@NP	significantly fewer axons	22427
@NP	the MP/EC group	22458
@NP	N ; 22.48 ± 6.00	22475
@NP	N	22475
@NP	22.48 ± 6.00	22478
@NP	22.48 ±	22478
@NP	6.00	22486
@NP	There	22493
@NP	significantly more axons in the sham group	22503
@NP	significantly more axons	22503
@NP	the sham group	22531
@NP	all the other groups at this distance -LRB- Q ; 53.26 ± 3.88 -RRB-	22554
@NP	all the other groups	22554
@NP	this distance -LRB- Q ; 53.26 ± 3.88 -RRB-	22578
@NP	this distance	22578
@NP	Q ; 53.26 ± 3.88	22593
@NP	Q	22593
@NP	53.26 ± 3.88	22596
@NP	53.26 ±	22596
@NP	3.88	22604
@NP	19 mm	22614
@NP	the lesion -LRB- C ; 0.02 ± 0.02 -RRB-	22621
@NP	the lesion	22621
@NP	C ; 0.02 ± 0.02	22633
@NP	C	22633
@NP	0.02 ± 0.02	22636
@NP	0.02	22636
@NP	± 0.02	22641
@NP	vehicle -LRB- F ; 0.04 ± 0.04 -RRB-	22650
@NP	vehicle	22650
@NP	F ; 0.04 ± 0.04	22659
@NP	F	22659
@NP	0.04 ± 0.04	22662
@NP	0.04 ±	22662
@NP	0.04	22669
@NP	MP -LRB- I ; 0.18 ± 0.03 -RRB-	22680
@NP	MP	22680
@NP	I ; 0.18 ± 0.03	22683
@NP	I	22683
@NP	0.18 ± 0.03	22686
@NP	0.18	22686
@NP	± 0.03	22691
@NP	groups	22699
@NP	The EC -LRB- L ; 2.18 ± 0.16 -RRB- and MP/EC -LRB- O ; 2.23 ± 0.20 -RRB- groups	22745
@NP	The EC -LRB- L ; 2.18 ± 0.16 -RRB-	22745
@NP	The EC	22745
@NP	L ; 2.18 ± 0.16	22753
@NP	L	22753
@NP	2.18 ± 0.16	22756
@NP	2.18 ±	22756
@NP	0.16	22763
@NP	MP/EC -LRB- O ; 2.23 ± 0.20 -RRB- groups	22773
@NP	MP/EC	22773
@NP	O ; 2.23 ± 0.20	22780
@NP	O	22780
@NP	2.23 ± 0.20	22783
@NP	2.23 ±	22783
@NP	0.20	22790
@NP	groups	22796
@NP	significantly more axons than all other lesioned groups	22808
@NP	significantly more axons	22808
@NP	all other lesioned groups	22838
@NP	there	22869
@NP	no significant difference between these groups	22878
@NP	no significant difference	22878
@NP	these groups	22912
@NP	The sham group	22926
@NP	significantly more axons	22945
@NP	all other groups at this distance -LRB- R ; 52.19 ± 2.96 -RRB-	22975
@NP	all other groups	22975
@NP	this distance -LRB- R ; 52.19 ± 2.96 -RRB-	22995
@NP	this distance	22995
@NP	R ; 52.19 ± 2.96	23010
@NP	R	23010
@NP	52.19 ± 2.96	23013
@NP	52.19 ±	23013
@NP	2.96	23021
@NP	Scale bar , 50 µm .	23028
@NP	Scale bar	23028
@NP	50 µm	23039
@NP	Figure 4 .	23047
@NP	Figure	23047
@NP	4	23054
@NP	Graphical and tabular presentation of the axonal data .	23057
@NP	Graphical and tabular presentation of the axonal data	23057
@NP	Graphical	23057
@NP	tabular presentation of the axonal data	23071
@NP	tabular presentation	23071
@NP	the axonal data	23095
@NP	Graphs	23112
@NP	the mean number of axons for the lesion , vehicle , MP , EC , and MP/EC groups	23122
@NP	the mean number	23122
@NP	axons for the lesion , vehicle , MP , EC , and MP/EC groups	23141
@NP	axons	23141
@NP	the lesion , vehicle , MP , EC , and MP/EC groups	23151
@NP	1 mm -LRB- A -RRB- , 10 mm -LRB- B -RRB- , and 19 mm -LRB- C -RRB-	23200
@NP	1 mm -LRB- A -RRB-	23200
@NP	A	23206
@NP	10 mm -LRB- B -RRB-	23210
@NP	B	23217
@NP	19 mm -LRB- C -RRB-	23225
@NP	C	23232
@NP	caudal to the lesion	23235
@NP	caudal	23235
@NP	the lesion	23245
@NP	the axon means	23265
@NP	all distances relative to the axon means for the other groups	23295
@NP	all distances	23295
@NP	the axon	23321
@NP	the other groups	23340
@NP	the data for the sham group	23358
@NP	the data	23358
@NP	the sham group	23371
@NP	1 mm caudal	23420
@NP	the lesion -LRB- A -RRB-	23435
@NP	the lesion	23435
@NP	A	23447
@NP	The table -LRB- D -RRB-	23451
@NP	The table	23451
@NP	D	23462
@NP	the complete set of data	23488
@NP	the complete set	23488
@NP	data	23508
@NP	the axon	23517
@NP	the seven distances -LRB- 1 , 4 , 7 , 10 , 13 , 16 , and 19 mm -RRB- caudal	23536
@NP	seven distances -LRB- 1 , 4 , 7 , 10 , 13 , 16 , and 19 mm -RRB-	23540
@NP	seven distances	23540
@NP	1 , 4 , 7 , 10 , 13 , 16 , and 19 mm	23557
@NP	1	23557
@NP	4	23560
@NP	7	23563
@NP	10	23566
@NP	13	23570
@NP	16	23574
@NP	19 mm	23582
@NP	the lesion for the three control	23599
@NP	the lesion	23599
@NP	the three control	23614
@NP	three experimental groups used in this study	23636
@NP	three experimental groups	23636
@NP	this study	23670
@NP	Data	23682
@NP	mean ± SEM number of axons	23704
@NP	mean ± SEM number	23704
@NP	axons	23725
@NP	Figure 5 .	23733
@NP	Figure	23733
@NP	5	23740
@NP	ECs	23743
@NP	axons	23764
@NP	Photomicrographs of BDTlabeled CST axons -LRB- red -RRB-	23771
@NP	Photomicrographs of BDTlabeled CST axons	23771
@NP	Photomicrographs	23771
@NP	BDTlabeled CST axons	23791
@NP	red	23813
@NP	Cell Tracker green-labeled ECs	23832
@NP	Cell	23832
@NP	Tracker green-labeled ECs	23837
@NP	ECs in both the EC and MP/EC groups	23864
@NP	ECs	23864
@NP	both the EC and MP/EC groups	23871
@NP	the EC	23876
@NP	MP/EC groups	23887
@NP	all distances	23908
@NP	representative images	23927
@NP	1 mm -LRB- A and B , respectively -RRB-	23964
@NP	A and B , respectively	23970
@NP	A and B	23970
@NP	7 mm -LRB- C and D -RRB-	23994
@NP	C and D	24000
@NP	C	24000
@NP	D	24006
@NP	13 mm -LRB- E and F -RRB-	24010
@NP	E and F	24017
@NP	E	24017
@NP	F	24023
@NP	19 mm -LRB- G and H -RRB-	24031
@NP	G and H	24038
@NP	G	24038
@NP	H	24044
@NP	the farthest distance analyzed	24048
@NP	the farthest distance	24048
@NP	Scale bar , 50 µm .	24080
@NP	Scale bar	24080
@NP	50 µm	24091
@NP	Immediate postoperative observations	24099
@NP	the week	24143
@NP	surgery	24158
@NP	all animals	24167
@NP	lack of bladder control , wound opening , and signs of infection	24197
@NP	lack	24197
@NP	bladder control , wound opening , and signs of infection	24205
@NP	bladder control	24205
@NP	wound opening	24222
@NP	signs of infection	24241
@NP	signs	24241
@NP	infection	24250
@NP	neurological deficits	24301
@NP	some animals	24327
@NP	a slight paresis and/or ataxia	24341
@NP	a slight paresis	24341
@NP	ataxia	24365
@NP	these symptoms	24387
@NP	2 weeks of surgery	24418
@NP	2 weeks	24418
@NP	surgery	24429
@NP	Functional recovery Rats	24438
@NP	surgery	24482
@NP	a DFR presurgery baseline	24503
@NP	This presurgical baseline	24530
@NP	all rats	24569
@NP	the DFR task	24618
@NP	differences in presurgical ability	24660
@NP	differences	24660
@NP	presurgical ability	24675
@NP	the postsurgical scores	24712
@NP	all rats	24737
@NP	the DFR task	24771
@NP	a success rate of at least 90 %	24787
@NP	a success rate	24787
@NP	at least 90 %	24805
@NP	the beginning of Materials and Methods	24831
@NP	the beginning	24831
@NP	Materials and Methods	24848
@NP	Materials	24848
@NP	Methods	24862
@NP	two rats	24871
@NP	this level	24899
@NP	the study	24945
@NP	All other rats	24956
@NP	the criterion	24975
@NP	inclusion in the study	25003
@NP	inclusion	25003
@NP	the study	25016
@NP	The presurgery DFR scores -LRB- Fig. 1C -RRB- for each group	25027
@NP	The presurgery DFR scores -LRB- Fig. 1C -RRB-	25027
@NP	The presurgery DFR scores	25027
@NP	Fig. 1C	25054
@NP	each group	25067
@NP	sham	25095
@NP	95.95 ± 3.91	25101
@NP	95.95 ±	25101
@NP	3.91	25109
@NP	lesion , 95.19 ± 3.72	25115
@NP	lesion	25115
@NP	95.19 ± 3.72	25123
@NP	95.19	25123
@NP	± 3.72	25129
@NP	vehicle , 95.41 ± 4.11	25137
@NP	vehicle	25137
@NP	95.41 ± 4.11	25146
@NP	95.41 ±	25146
@NP	4.11	25154
@NP	MP , 95.20 ± 4.59	25160
@NP	MP	25160
@NP	95.20 ± 4.59	25164
@NP	95.20	25164
@NP	± 4.59	25170
@NP	EC , 94.40 ± 3.47	25178
@NP	EC	25178
@NP	94.40 ± 3.47	25182
@NP	94.40 ±	25182
@NP	3.47	25190
@NP	MP/EC , 93.97 ± 3.89	25200
@NP	MP/EC	25200
@NP	93.97 ± 3.89	25207
@NP	93.97 ±	25207
@NP	3.89	25215
@NP	the sixth week after injury	25228
@NP	the sixth week	25228
@NP	injury	25249
@NP	rats	25257
@NP	their ability to perform the DFR task -LRB- Fig. 1D -RRB-	25284
@NP	the DFR task -LRB- Fig. 1D -RRB-	25309
@NP	the DFR task	25309
@NP	Fig. 1D	25323
@NP	this functional test	25339
@NP	the sham animals	25361
@NP	the DFR task	25388
@NP	94.86 ± 3.86 %	25425
@NP	94.86	25425
@NP	± 3.86 %	25431
@NP	they	25443
@NP	This finding	25467
@NP	only the lesion , and no other portion of the surgical procedure ,	25498
@NP	only the lesion	25498
@NP	no other portion of the surgical procedure	25519
@NP	no other portion	25519
@NP	the surgical procedure	25539
@NP	the rats ' abilities to perform the DFR task	25573
@NP	the rats '	25573
@NP	the DFR task	25604
@NP	the sham group	25637
@NP	a significant functional deficit	25653
@NP	all rats that were lesioned	25699
@NP	all rats	25699
@NP	their treatment group	25742
@NP	this functional deficit in performing the DFR task	25774
@NP	this functional deficit	25774
@NP	the DFR task	25812
@NP	the same	25833
@NP	all of the experimental groups	25849
@NP	all	25849
@NP	the experimental groups	25856
@NP	The lesion and vehicle groups	25881
@NP	the most impaired of all of the groups	25916
@NP	the most impaired	25916
@NP	all of the groups	25937
@NP	all	25937
@NP	the groups	25944
@NP	surgery	25961
@NP	The lesion and vehicle groups	25970
@NP	the DFR task	26021
@NP	a success rate of only 38.38 ± 8.31 and 42.41 ± 7.10 %	26039
@NP	a success rate of only 38.38 ± 8.31	26039
@NP	a success rate	26039
@NP	only 38.38 ± 8.31	26057
@NP	42.41 ± 7.10 %	26079
@NP	42.41 ±	26079
@NP	7.10 %	26087
@NP	there	26108
@NP	no significant difference between these two groups	26118
@NP	no significant difference	26118
@NP	these two groups	26152
@NP	The MP group , with a success rate of 56.66 ± 5.63 % ,	26170
@NP	The MP group	26170
@NP	a success rate of 56.66 ±	26189
@NP	a success rate	26189
@NP	56.66 ±	26207
@NP	5.63 %	26215
@NP	the lesion and vehicle groups	26258
@NP	The EC group	26289
@NP	the DFR task significantly better	26312
@NP	the DFR task	26312
@NP	the lesion , vehicle , and MP groups	26351
@NP	the lesion	26351
@NP	vehicle	26363
@NP	MP groups	26376
@NP	a success rate of 71.84 ± 5.20 %	26392
@NP	a success rate	26392
@NP	71.84 ± 5.20 %	26410
@NP	71.84 ±	26410
@NP	5.20 %	26418
@NP	the EC group	26430
@NP	the MP/EC group , with a success rate of 78.26 ± 6.68 % ,	26444
@NP	the MP/EC group	26444
@NP	a success rate of 78.26 ±	26466
@NP	a success rate	26466
@NP	78.26 ±	26484
@NP	6.68 %	26492
@NP	the DFR task significantly better	26509
@NP	the DFR task	26509
@NP	the lesion , vehicle , and MP groups	26548
@NP	the lesion	26548
@NP	vehicle	26560
@NP	MP groups	26573
@NP	the group that received the combination treatment of ECs and MP	26593
@NP	the group	26593
@NP	the combination treatment of ECs and MP	26617
@NP	the combination treatment	26617
@NP	ECs and MP	26646
@NP	the DFR task	26667
@NP	a higher success rate -LRB- 78.26 % -RRB-	26685
@NP	a higher success rate	26685
@NP	78.26 %	26708
@NP	the group that received ECs alone -LRB- 71.84 % -RRB-	26721
@NP	the group	26721
@NP	ECs	26745
@NP	71.84 %	26756
@NP	this difference	26765
@NP	Histology and axonal counts Fluorogold-labeled neurons The primary motor cortex	26816
@NP	Histology	26816
@NP	axonal counts Fluorogold-labeled neurons The primary motor cortex	26830
@NP	axonal counts	26830
@NP	Fluorogold-labeled neurons	26844
@NP	The primary motor cortex	26871
@NP	all rats used in this study	26912
@NP	all rats	26912
@NP	this study	26929
@NP	All of the brains	26941
@NP	All	26941
@NP	the brains	26948
@NP	Fluorogold-labeled neurons	26969
@NP	layer V of the primary motor cortex	26999
@NP	layer V	26999
@NP	the primary motor cortex	27010
@NP	the dorsal CST axons	27052
@NP	the dorsal	27052
@NP	CST axons	27063
@NP	the lesioning procedure -LRB- Fig. 2 -RRB-	27096
@NP	the lesioning procedure	27096
@NP	Fig. 2	27121
@NP	all CST axons located in the dorsal funiculus	27138
@NP	all CST axons	27138
@NP	the dorsal funiculus	27163
@NP	surgery	27207
@NP	just those in the forelimb representation	27223
@NP	just those	27223
@NP	the forelimb representation	27237
@NP	Fluorogold-labeled neurons	27266
@NP	the primary motor cortex in layer V.	27315
@NP	the primary motor cortex	27315
@NP	layer V.	27343
@NP	Unlabeled pyramidal neurons	27352
@NP	the primary motor cortex in layer V.	27417
@NP	the primary motor cortex	27417
@NP	layer V.	27445
@NP	It	27454
@NP	these neurons	27474
@NP	uncrossed CST axons located in the ventral funiculus of the spinal cord	27502
@NP	uncrossed CST axons	27502
@NP	the ventral funiculus of the spinal cord	27533
@NP	the ventral funiculus	27533
@NP	the spinal cord	27558
@NP	The only exception to this labeling pattern	27575
@NP	The only exception	27575
@NP	this labeling pattern	27597
@NP	the brains	27626
@NP	the rats that were in the sham group , whose brains had no Fluorogold label	27640
@NP	the rats	27640
@NP	the sham group , whose brains had no Fluorogold label	27662
@NP	the sham group	27662
@NP	no Fluorogold label	27695
@NP	Biotin dextran tetramethylrhodamine-labeled axons All of the groups	27716
@NP	Biotin dextran	27716
@NP	tetramethylrhodamine-labeled axons	27731
@NP	All of the groups	27766
@NP	All	27766
@NP	the groups	27773
@NP	some CST axonal growth caudal	27791
@NP	the lesion	27824
@NP	regrowth	27845
@NP	all of the animals in every group	27883
@NP	all	27883
@NP	the animals in every group	27890
@NP	the animals	27890
@NP	every group	27905
@NP	There	27918
@NP	three rats	27929
@NP	two lesion and one vehicle	27941
@NP	two lesion	27941
@NP	one vehicle	27956
@NP	any BDT-labeled CST axons caudal to the lesion site	27987
@NP	any BDT-labeled CST	27987
@NP	axons	28007
@NP	the lesion site	28023
@NP	the lack of labeled CST axons	28055
@NP	the lack	28055
@NP	labeled CST axons	28067
@NP	a problem with the BDT or the labeling technique	28105
@NP	a problem	28105
@NP	the BDT or the labeling technique	28120
@NP	the BDT	28120
@NP	the labeling technique	28131
@NP	the spinal cords of these three rats	28155
@NP	the spinal cords	28155
@NP	these three rats	28175
@NP	rostral	28206
@NP	the lesion	28217
@NP	All three	28229
@NP	BDT-labeled CST axons	28258
@NP	the injury site	28292
@NP	all groups	28312
@NP	CST axons	28324
@NP	course	28348
@NP	the white matter of the dorsal funiculus	28358
@NP	the white matter	28358
@NP	the dorsal funiculus	28378
@NP	occasion	28407
@NP	the gray matter	28436
@NP	these CST axons	28458
@NP	the gray matter	28491
@NP	they	28508
@NP	the border between the gray and white matter	28527
@NP	the border	28527
@NP	the gray and white matter	28546
@NP	those rats that received EC transplants	28576
@NP	those rats	28576
@NP	EC transplants	28601
@NP	ECs	28617
@NP	the spinal cord white matter	28654
@NP	they	28693
@NP	the spinal cord gray matter	28719
@NP	the ECs	28757
@NP	the length of the axons	28808
@NP	the length	28808
@NP	the axons	28822
@NP	the ECs	28833
@NP	all areas in which regrowing axons were seen	28855
@NP	all areas	28855
@NP	regrowing axons	28874
@NP	The tissue	28901
@NP	19 mm caudal	28931
@NP	the lesion	28947
@NP	ECs	28963
@NP	this distance	28983
@NP	densities	29001
@NP	all distances analyzed at 4 mm caudal to the lesion and beyond	29056
@NP	all distances	29056
@NP	4 mm caudal to the lesion and beyond	29082
@NP	4 mm caudal	29082
@NP	the lesion	29097
@NP	ECs	29129
@NP	1 mm caudal	29164
@NP	the lesion	29179
@NP	The number of BDT-labeled axons present	29191
@NP	The number	29191
@NP	BDT-labeled axons present	29205
@NP	BDT-labeled axons	29205
@NP	all control and experimental groups	29248
@NP	all control	29248
@NP	experimental groups	29264
@NP	1 , 4 , 7 , 10 , 13 , 16 , and 19 mm caudal	29287
@NP	1	29287
@NP	4	29290
@NP	7	29293
@NP	10	29296
@NP	13	29300
@NP	16	29304
@NP	19 mm caudal	29312
@NP	the lesion site	29328
@NP	A representative photomicrograph	29345
@NP	each group -LRB- Fig. 3 -RRB-	29383
@NP	each group	29383
@NP	Fig. 3	29395
@NP	a graph comparing the means from the groups -LRB- Fig. 4A -- C -RRB-	29407
@NP	a graph	29407
@NP	the means	29425
@NP	the groups -LRB- Fig. 4A -- C -RRB-	29440
@NP	the groups	29440
@NP	Fig. 4A -- C	29452
@NP	Fig. 4A	29452
@NP	C	29460
@NP	1 , 10 , and 19 mm	29481
@NP	1	29481
@NP	10	29484
@NP	19 mm	29492
@NP	Figure 4D	29512
@NP	the mean number of labeled axons for each group at all of the distances examined	29525
@NP	the mean number	29525
@NP	axons for each group	29552
@NP	axons	29552
@NP	each group	29562
@NP	all of the distances examined	29576
@NP	all	29576
@NP	the distances examined	29583
@NP	the distances	29583
@NP	Differences between the means of groups	29607
@NP	Differences	29607
@NP	the means of groups	29627
@NP	the means	29627
@NP	groups	29640
@NP	most of the graphs	29678
@NP	most	29678
@NP	the graphs	29686
@NP	the sham group data	29702
@NP	the means for the sham group	29744
@NP	the means	29744
@NP	the sham group	29758
@NP	the means of all the other groups	29795
@NP	the means	29795
@NP	all the other groups	29808
@NP	1 mm	29840
@NP	the data for the sham group	29857
@NP	the data	29857
@NP	the sham group	29870
@NP	Figure 4A , which presents the data for the groups at 1 mm caudal to the lesion	29921
@NP	Figure 4A	29921
@NP	the data for the groups	29947
@NP	the data	29947
@NP	the groups	29960
@NP	1 mm caudal to the lesion	29974
@NP	1 mm caudal	29974
@NP	the lesion	29989
@NP	all	30012
@NP	the	30019
@NP	intervals	30032
@NP	the mean number of axons	30043
@NP	the mean number	30043
@NP	axons	30062
@NP	highest in the sham group -LRB- Fig. 4D -RRB-	30073
@NP	highest	30073
@NP	the sham group -LRB- Fig. 4D -RRB-	30084
@NP	the sham group	30084
@NP	Fig. 4D	30100
@NP	each distance examined	30118
@NP	each distance	30118
@NP	the mean number of labeled axons in the sham group	30142
@NP	the mean number	30142
@NP	labeled axons in the sham group	30161
@NP	labeled axons	30161
@NP	the sham group	30178
@NP	all other groups	30226
@NP	one exception , which is noted below	30249
@NP	one exception	30249
@NP	the functional data reported above	30297
@NP	the functional data	30297
@NP	there	30333
@NP	no significant difference	30343
@NP	the means	30377
@NP	the lesion and vehicle groups at any distance examined -LRB- Fig. 4 -RRB-	30390
@NP	the lesion and vehicle groups	30390
@NP	any distance examined	30423
@NP	any distance	30423
@NP	Fig. 4	30446
@NP	these two groups	30458
@NP	axons	30476
@NP	only a short distance caudal	30493
@NP	the injury -LRB- Fig. 4A -RRB-	30525
@NP	the injury	30525
@NP	Fig. 4A	30537
@NP	10 mm	30555
@NP	the lesion -LRB- Fig. 4B -RRB-	30571
@NP	the lesion	30571
@NP	Fig. 4B	30583
@NP	the farthest distance examined	30595
@NP	the farthest distance	30595
@NP	Fig. 4C	30627
@NP	all of the tissue	30637
@NP	all	30637
@NP	the tissue	30644
@NP	axons in both the lesion -LRB- Figs. 3A -- C , 4D -RRB-	30679
@NP	axons	30679
@NP	both the lesion -LRB- Figs. 3A -- C , 4D -RRB-	30688
@NP	both the lesion	30688
@NP	Figs. 3A	30705
@NP	C , 4D	30714
@NP	C	30714
@NP	4D	30717
@NP	vehicle -LRB- Figs. 3D -- F , 4D -RRB- groups	30725
@NP	vehicle	30725
@NP	Figs. 3D	30734
@NP	F , 4D	30743
@NP	F	30743
@NP	4D	30746
@NP	groups	30750
@NP	the MP group	30761
@NP	axons	30775
@NP	7 mm	30804
@NP	10 mm	30822
@NP	the MP	30840
@NP	very few labeled axons -LRB- Figs. 3G -- I , 4D -RRB-	30851
@NP	very few	30851
@NP	axons -LRB- Figs. 3G -- I , 4D -RRB-	30868
@NP	axons	30868
@NP	Figs. 3G	30875
@NP	I , 4D	30884
@NP	I	30884
@NP	4D	30887
@NP	the MP group	30921
@NP	significantly more axons	30938
@NP	the lesion and vehicle groups	30968
@NP	1 , 4 , and 7 mm -LRB- Fig. 4A , D -RRB-	31001
@NP	1	31001
@NP	4	31004
@NP	7 mm	31011
@NP	Fig. 4A , D	31017
@NP	Fig. 4A	31017
@NP	D	31025
@NP	10 , 13 , 16 , and 19 mm	31041
@NP	10	31041
@NP	13	31045
@NP	16	31049
@NP	19 mm	31057
@NP	no significant differences	31064
@NP	the means of these three groups -LRB- Fig. 4B -- D -RRB-	31108
@NP	the means	31108
@NP	these three groups -LRB- Fig. 4B -- D -RRB-	31121
@NP	these three groups	31121
@NP	Fig. 4B -- D	31141
@NP	Fig. 4B	31141
@NP	D	31149
@NP	the photomicrographs of the tissue	31166
@NP	the photomicrographs	31166
@NP	the tissue	31190
@NP	the EC group -LRB- Fig. 3J -- L -RRB-	31206
@NP	the EC group	31206
@NP	Fig. 3J -- L	31220
@NP	Fig. 3J	31220
@NP	L	31228
@NP	it	31232
@NP	this group	31252
@NP	more labeled axons	31272
@NP	the lesion	31296
@NP	Fig. 3A -- C	31308
@NP	Fig. 3A	31308
@NP	C	31316
@NP	Fig. 3D -- F	31329
@NP	Fig. 3D	31329
@NP	F	31337
@NP	Fig. 3G -- I	31348
@NP	Fig. 3G	31348
@NP	I	31356
@NP	groups	31359
@NP	the number of labeled axons	31376
@NP	the number	31376
@NP	labeled axons	31390
@NP	proportion to distance caudal	31417
@NP	proportion	31417
@NP	distance caudal	31431
@NP	the injury -LRB- Fig. 4D -RRB-	31450
@NP	the injury	31450
@NP	Fig. 4D	31462
@NP	axons	31472
@NP	the farthest distance analyzed -LRB- Fig. 3L -RRB-	31499
@NP	the farthest distance	31499
@NP	Fig. 3L	31531
@NP	all tissue examined in the EC group	31544
@NP	all tissue	31544
@NP	the EC group	31567
@NP	Cell Tracker	31581
@NP	ECs	31607
@NP	the areas in which regrowing axons were located -LRB- Fig. 5 -RRB-	31625
@NP	the areas	31625
@NP	regrowing axons	31644
@NP	Fig. 5	31674
@NP	Analysis of the data	31683
@NP	Analysis	31683
@NP	the data	31695
@NP	the lesion , vehicle , and MP groups	31737
@NP	the lesion	31737
@NP	vehicle	31749
@NP	MP groups	31762
@NP	the EC group	31773
@NP	significantly more axons	31790
@NP	all distances examined -LRB- Fig. 4 -RRB-	31818
@NP	all distances	31818
@NP	Fig. 4	31842
@NP	These data	31851
@NP	the functional findings	31870
@NP	the rats receiving ECs	31919
@NP	the rats	31919
@NP	ECs	31938
@NP	significantly more CST function	31951
@NP	the lesion , vehicle , and MP groups	31988
@NP	the lesion	31988
@NP	vehicle	32000
@NP	MP groups	32013
@NP	1 mm distal to the injury	32027
@NP	1 mm	32027
@NP	the injury	32042
@NP	the mean of theMP/EC group	32054
@NP	the mean	32054
@NP	theMP/EC group	32066
@NP	the rats in the sham control group -LRB- Figs. 3A , P , 4A , D -RRB-	32118
@NP	the rats	32118
@NP	the sham control group -LRB- Figs. 3A , P , 4A , D -RRB-	32130
@NP	the sham control group	32130
@NP	Figs. 3A	32154
@NP	P , 4A , D	32163
@NP	1 mm	32179
@NP	the sham group	32185
@NP	significantly more axons	32204
@NP	the MP/EC group -LRB- Figs. 3M -- R , 4 -RRB-	32234
@NP	the MP/EC group	32234
@NP	Figs. 3M -- R , 4	32251
@NP	Figs. 3M	32251
@NP	R , 4	32260
@NP	R	32260
@NP	the EC group	32275
@NP	the number of labeled axons in the MP/EC group	32289
@NP	the number	32289
@NP	labeled axons in the MP/EC group	32303
@NP	labeled axons	32303
@NP	the MP/EC group	32320
@NP	distance	32349
@NP	the lesion increased -LRB- Fig. 3M -- O , 4D -RRB-	32363
@NP	the lesion	32363
@NP	Fig. 3M -- O , 4D	32385
@NP	Fig. 3M	32385
@NP	O , 4D	32393
@NP	O	32393
@NP	4D	32396
@NP	axons	32405
@NP	19 mm -LRB- Fig. 3O -RRB-	32434
@NP	19 mm	32434
@NP	Fig. 3O	32441
@NP	the EC group	32457
@NP	the MP/EC group	32471
@NP	ECs	32497
@NP	the regions in which axons were found -LRB- Fig. 5 -RRB-	32530
@NP	the regions	32530
@NP	axons	32551
@NP	Fig. 5	32569
@NP	Statistical analysis	32578
@NP	the MP/EC group	32613
@NP	significantly more axons	32633
@NP	the lesion , vehicle , and MP groups	32663
@NP	the lesion	32663
@NP	vehicle	32675
@NP	MP groups	32688
@NP	all distances examined -LRB- Fig. 4 -RRB-	32701
@NP	all distances examined	32701
@NP	all distances	32701
@NP	Fig. 4	32725
@NP	the functional findings presented above	32752
@NP	the functional findings	32752
@NP	the means	32798
@NP	the group	32813
@NP	the combined treatment	32837
@NP	the means	32879
@NP	the group that received only ECs , significant differences in results	32894
@NP	the group	32894
@NP	only ECs , significant differences in results	32918
@NP	only ECs	32918
@NP	significant differences in results	32928
@NP	significant differences	32928
@NP	results	32955
@NP	most distances	32975
@NP	the injury -LRB- Fig. 4 -RRB-	33000
@NP	the injury	33000
@NP	Fig. 4	33012
@NP	Analysis of the data from 1 , 4 , 7 , 10 , and 13 mm	33021
@NP	Analysis	33021
@NP	the data from 1 , 4 , 7 , 10 , and 13 mm	33033
@NP	the data	33033
@NP	1 , 4 , 7 , 10 , and 13 mm	33047
@NP	1	33047
@NP	4	33050
@NP	7	33053
@NP	10	33056
@NP	13 mm	33064
@NP	the MP/EC group	33088
@NP	significantly more axons	33108
@NP	the EC group -LRB- Fig. 4A , B , D -RRB-	33138
@NP	the EC group	33138
@NP	Fig. 4A	33152
@NP	B	33160
@NP	D	33162
@NP	no significant differences between the means of these two groups	33175
@NP	no significant differences	33175
@NP	the means of these two groups	33210
@NP	the means	33210
@NP	these two groups	33223
@NP	16 and 19 mm caudal	33254
@NP	16	33254
@NP	19 mm caudal	33261
@NP	the lesion -LRB- Fig. 4C , D -RRB-	33277
@NP	the lesion	33277
@NP	Fig. 4C , D	33289
@NP	Fig. 4C	33289
@NP	D	33297
@NP	This lack	33301
@NP	significant differences	33314
@NP	the means of the EC and MP/EC groups at the farthest distances analyzed	33346
@NP	the means	33346
@NP	the EC and MP/EC groups at the farthest distances analyzed	33359
@NP	the EC and MP/EC groups	33359
@NP	the farthest distances analyzed	33386
@NP	the farthest distances	33386
@NP	the lack	33430
@NP	a significant difference between the DFR performance of these two groups	33442
@NP	a significant difference	33442
@NP	the DFR performance of these two groups	33475
@NP	the DFR performance	33475
@NP	these two groups	33498
@NP	functional differences	33540
@NP	a longer recovery period	33568
@NP	DISCUSSION	33595
@NP	there	33617
@NP	no treatment regimen	33626
@NP	sensory and motor function	33668
@NP	SCI in humans	33714
@NP	SCI	33714
@NP	humans	33721
@NP	progress	33738
@NP	animal research	33764
@NP	Numerous treatment strategies	33781
@NP	damaged axons	33844
@NP	SCI	33864
@NP	rats	33871
@NP	David and Aguayo	33877
@NP	1981	33895
@NP	Goldberg and Bernstein , 1987	33901
@NP	Goldberg and Bernstein	33901
@NP	1987	33925
@NP	Schnell and Schwab , 1993	33931
@NP	Schnell and Schwab	33931
@NP	1993	33951
@NP	Joosten et al. , 1995	33957
@NP	Joosten	33957
@NP	et al. , 1995	33965
@NP	et al.	33965
@NP	1995	33973
@NP	Xu et al. , 1995	33979
@NP	Xu	33979
@NP	et al. , 1995	33982
@NP	et al.	33982
@NP	1995	33990
@NP	Chen et al. , 1996	33996
@NP	Chen	33996
@NP	et al. , 1996	34001
@NP	et al.	34001
@NP	1996	34009
@NP	Kalderon and Fuks , 1996	34015
@NP	Kalderon and Fuks	34015
@NP	1996	34034
@NP	Bregman et al. , 1997	34040
@NP	Bregman	34040
@NP	et al. , 1997	34048
@NP	et al.	34048
@NP	1997	34056
@NP	Guest et al. , 1997	34062
@NP	Guest	34062
@NP	et al. , 1997	34068
@NP	et al.	34068
@NP	1997	34076
@NP	Oudega et al. , 1997	34082
@NP	Oudega	34082
@NP	et al. , 1997	34089
@NP	et al.	34089
@NP	1997	34097
@NP	Ye and Houle , 1997	34103
@NP	Ye	34103
@NP	Houle , 1997	34110
@NP	Houle	34110
@NP	1997	34117
@NP	Ramon-Cueto et al.	34123
@NP	Ramon-Cueto	34123
@NP	et al.	34135
@NP	1998	34143
@NP	these strategies	34156
@NP	the transplantation	34177
@NP	various cell types	34200
@NP	fetal cells	34230
@NP	Kunkel-Bagden and Bregman	34243
@NP	Kunkel-Bagden	34243
@NP	Bregman	34261
@NP	1990	34270
@NP	Bernstein-Goral and Bregman , 1997	34276
@NP	Bernstein-Goral and Bregman	34276
@NP	1997	34305
@NP	Mori et al. , 1997	34311
@NP	Mori	34311
@NP	et al. , 1997	34316
@NP	et al.	34316
@NP	1997	34324
@NP	Bregman et al. , 1998	34330
@NP	Bregman	34330
@NP	et al. , 1998	34338
@NP	et al.	34338
@NP	1998	34346
@NP	Diener and Bregman , 1998a	34352
@NP	Diener and Bregman	34352
@NP	1998a	34372
@NP	McDonald , 1999	34379
@NP	McDonald	34379
@NP	1999	34389
@NP	Schwann cells	34399
@NP	Kuhlengel	34414
@NP	et al. , 1990	34424
@NP	et al.	34424
@NP	1990	34432
@NP	Li and Raisman , 1994	34438
@NP	Li and Raisman	34438
@NP	1994	34454
@NP	Xu et al. , 1995	34460
@NP	Xu	34460
@NP	et al. , 1995	34463
@NP	et al.	34463
@NP	1995	34471
@NP	Chen et al. , 1996	34477
@NP	Chen	34477
@NP	et al. , 1996	34482
@NP	et al.	34482
@NP	1996	34490
@NP	Martin et al. , 1996	34496
@NP	Martin	34496
@NP	et al. , 1996	34503
@NP	et al.	34503
@NP	1996	34511
@NP	Guest et al. , 1997	34517
@NP	Guest	34517
@NP	et al. , 1997	34523
@NP	et al.	34523
@NP	1997	34531
@NP	Fetal spinal cord transplants	34538
@NP	the regrowth	34595
@NP	CST , raphespinal , and rubrospinal axons -LRB- Diener and Bregman , 1998b -RRB-	34611
@NP	CST	34611
@NP	raphespinal	34616
@NP	rubrospinal axons	34633
@NP	Diener and Bregman	34652
@NP	1998b	34672
@NP	functional recovery	34699
@NP	injuries to the neonatal spinal cord -LRB- Diener and Bregman , 1998a -RRB-	34725
@NP	injuries	34725
@NP	the neonatal spinal cord -LRB- Diener and Bregman , 1998a -RRB-	34737
@NP	the neonatal spinal cord	34737
@NP	Diener and Bregman	34763
@NP	1998a	34783
@NP	The transplantation	34791
@NP	murine embryonic stem cells into lesioned adult rat spinal cords	34814
@NP	murine embryonic stem cells	34814
@NP	lesioned adult rat spinal cords	34847
@NP	enhanced weight bearing	34895
@NP	coordination of hindlimbs -LRB- McDonald , 1999 -RRB-	34923
@NP	coordination	34923
@NP	hindlimbs -LRB- McDonald , 1999 -RRB-	34939
@NP	hindlimbs	34939
@NP	McDonald , 1999	34950
@NP	McDonald	34950
@NP	1999	34960
@NP	there	34976
@NP	a number	34986
@NP	ethical issues	34998
@NP	the use	35025
@NP	embryonic tissues	35036
@NP	its use in a clinical setting	35083
@NP	its use	35083
@NP	a clinical setting	35094
@NP	Schwann cells	35114
@NP	regeneration	35160
@NP	SCI	35179
@NP	Schwann cells	35184
@NP	lesioning , resulting in reduced gliosis ,	35271
@NP	lesioning	35271
@NP	reduced gliosis	35295
@NP	Schwann cell survival	35321
@NP	regeneration of axons -LRB- Martin et al. , 1996 -RRB-	35357
@NP	regeneration	35357
@NP	axons -LRB- Martin et al. , 1996 -RRB-	35373
@NP	axons	35373
@NP	Martin	35380
@NP	et al. , 1996	35387
@NP	et al.	35387
@NP	1996	35395
@NP	Schwann cells	35415
@NP	-LRB- Li and Raisman , 1994 -RRB- , regrowth	35472
@NP	Li and Raisman	35473
@NP	1994	35489
@NP	the lesion -LRB- Xu et al. , 1997 -RRB-	35510
@NP	the lesion	35510
@NP	Xu	35522
@NP	et al. , 1997	35525
@NP	et al.	35525
@NP	1997	35533
@NP	combination with methylprednisolone , the regrowth of axons	35558
@NP	combination	35558
@NP	methylprednisolone , the regrowth of axons	35575
@NP	methylprednisolone	35575
@NP	the regrowth of axons	35595
@NP	the regrowth	35595
@NP	axons	35611
@NP	the lesion	35624
@NP	the host spinal cord	35640
@NP	modest functional improvement -LRB- Guest et al. , 1997 -RRB-	35673
@NP	modest functional improvement	35673
@NP	Guest	35704
@NP	et al. , 1997	35710
@NP	et al.	35710
@NP	1997	35718
@NP	transplanted Schwann cells	35734
@NP	axonal regrowth	35771
@NP	function	35799
@NP	Schwann cells	35809
@NP	the CNS	35845
@NP	A number	35854
@NP	studies	35868
@NP	Schwann cells	35892
@NP	a poor survivability rate in the presence of astrocytes	35911
@NP	a poor survivability rate	35911
@NP	the presence of astrocytes	35940
@NP	the presence	35940
@NP	astrocytes	35956
@NP	their ability to remyelinate	35972
@NP	their ability	35972
@NP	remyelinate	35989
@NP	Franklin and Blakemore , 1993 ; Iwaniuk et al. , 1999	36016
@NP	Franklin and Blakemore	36016
@NP	1993 ; Iwaniuk et al.	36040
@NP	1993	36040
@NP	Iwaniuk et al.	36046
@NP	Iwaniuk	36046
@NP	et al.	36054
@NP	1999	36062
@NP	an astrocyte-free environment	36072
@NP	Schwann cell remyelination	36103
@NP	Duncan et al. , 1988 ; Shields et al. , 2000	36154
@NP	Duncan	36154
@NP	et al. , 1988 ; Shields et al. , 2000	36161
@NP	et al. , 1988	36161
@NP	et al.	36161
@NP	1988	36169
@NP	Shields et al. , 2000	36175
@NP	Shields	36175
@NP	et al. , 2000	36183
@NP	et al.	36183
@NP	2000	36191
@NP	This	36198
@NP	because	36206
@NP	Schwann cells transplanted into the CNS	36224
@NP	Schwann cells	36224
@NP	the CNS	36256
@NP	CNS axon regeneration	36289
@NP	Schwann cells	36312
@NP	astrocytes	36353
@NP	a primary component of CNS lesion sites -LRB- Lakatos et al. , 2000 -RRB-	36365
@NP	a primary component	36365
@NP	CNS lesion sites -LRB- Lakatos et al. , 2000 -RRB-	36388
@NP	CNS lesion sites	36388
@NP	Lakatos	36406
@NP	et al. , 2000	36414
@NP	et al.	36414
@NP	2000	36422
@NP	The ideal candidate for CNS transplantation	36429
@NP	The ideal candidate	36429
@NP	CNS transplantation	36453
@NP	a cell type	36480
@NP	the CNS	36520
@NP	the CNS environment	36563
@NP	regeneration and remyelination	36603
@NP	A cell type that meets these criteria	36635
@NP	A cell type	36635
@NP	these criteria	36658
@NP	the EC	36676
@NP	Franklin and Barnett	36684
@NP	1997	36706
@NP	Ramon-Cueto and Avila , 1998 ; Bartolomei and Greer , 2000 ; Lakatos et al.	36712
@NP	Ramon-Cueto and Avila , 1998	36712
@NP	Ramon-Cueto and Avila	36712
@NP	1998	36735
@NP	Bartolomei and Greer , 2000	36741
@NP	Bartolomei and Greer	36741
@NP	2000	36763
@NP	Lakatos et al.	36769
@NP	Lakatos	36769
@NP	et al.	36777
@NP	2000	36785
@NP	regeneration	36818
@NP	SCI	36837
@NP	Investigators	36842
@NP	previously the ability of ECs	36870
@NP	previously the ability	36870
@NP	ECs	36896
@NP	axonal regeneration	36911
@NP	SCI	36937
@NP	Li	36942
@NP	et al.	36945
@NP	1997 , 1998 ; Imaizumi et al. , 2000 ; Ramon-Cueto et al. , 2000 ; Lu et al.	36953
@NP	1997 , 1998	36953
@NP	1997	36953
@NP	1998	36959
@NP	Imaizumi et al. , 2000	36965
@NP	Imaizumi	36965
@NP	et al. , 2000	36974
@NP	et al.	36974
@NP	2000	36982
@NP	Ramon-Cueto et al. , 2000	36988
@NP	Ramon-Cueto	36988
@NP	et al. , 2000	37000
@NP	et al.	37000
@NP	2000	37008
@NP	Lu et al.	37014
@NP	Lu	37014
@NP	et al.	37017
@NP	2001	37025
@NP	Our results	37032
@NP	data that has been reported previously regarding the ability of ECs	37052
@NP	data	37052
@NP	the ability of ECs	37101
@NP	the ability	37101
@NP	ECs	37116
@NP	axonal regeneration and functional recovery	37131
@NP	regeneration	37138
@NP	our study	37182
@NP	previous research	37193
@NP	Li et al. -LRB- 1998 -RRB- and Ramon-Cueto et al. -LRB- 2000 -RRB-	37214
@NP	Li et al. -LRB- 1998 -RRB-	37214
@NP	Li	37214
@NP	et al. -LRB- 1998 -RRB-	37217
@NP	et al.	37217
@NP	1998	37225
@NP	Ramon-Cueto et al. -LRB- 2000 -RRB-	37235
@NP	Ramon-Cueto	37235
@NP	et al. -LRB- 2000 -RRB-	37247
@NP	et al.	37247
@NP	2000	37255
@NP	the transplanted ECs	37267
@NP	the regrowth of CST axons grown through the lesioned site	37297
@NP	the regrowth	37297
@NP	CST axons grown through the lesioned site	37313
@NP	CST axons	37313
@NP	the lesioned site	37337
@NP	ECs	37369
@NP	recovery	37430
@NP	Li	37440
@NP	et al. , 1997 ; Ramon - Cueto et al. , 2000	37443
@NP	et al.	37443
@NP	1997 ; Ramon - Cueto et al.	37451
@NP	1997 ; Ramon	37451
@NP	1997	37451
@NP	Ramon	37457
@NP	Cueto et al.	37464
@NP	Cueto	37464
@NP	et al.	37470
@NP	2000	37478
@NP	a finding that our data supports	37485
@NP	a finding	37485
@NP	our data	37500
@NP	The ability of ECs	37519
@NP	The ability	37519
@NP	ECs	37534
@NP	axonal regeneration	37549
@NP	other therapies	37588
@NP	Ramon	37632
@NP	Cueto et al. , 1998	37639
@NP	Cueto	37639
@NP	et al.	37645
@NP	1998	37653
@NP	no one	37664
@NP	ECs in combination	37688
@NP	ECs	37688
@NP	combination	37695
@NP	MP	37712
@NP	The combined effects of these two therapies	37716
@NP	The combined effects	37716
@NP	these two therapies	37740
@NP	ECs	37796
@NP	use in humans	37825
@NP	use	37825
@NP	humans	37832
@NP	MP	37848
@NP	the only current treatment	37854
@NP	an acute SCI -LRB- Bracken et al. , 1984 , 1990 , 1997 -RRB-	37903
@NP	an acute SCI	37903
@NP	Bracken	37917
@NP	et al. , 1984 , 1990 , 1997	37925
@NP	et al.	37925
@NP	1984	37933
@NP	1990	37939
@NP	1997	37945
@NP	the experiments described herein	37955
@NP	the experiments	37955
@NP	MP	37988
@NP	axonal regeneration	38012
@NP	functional recovery	38044
@NP	SCI	38070
@NP	untreated rats	38093
@NP	These improvements	38109
@NP	complete restoration of DFR function -LRB- 57 % -RRB-	38198
@NP	complete restoration	38198
@NP	DFR function -LRB- 57 % -RRB-	38222
@NP	DFR function	38222
@NP	57 %	38236
@NP	the limited distance that axons	38266
@NP	the limited distance	38266
@NP	≈ 7 mm	38324
@NP	contrast	38335
@NP	treatment with ECs	38345
@NP	treatment	38345
@NP	ECs	38360
@NP	axonal elongation	38376
@NP	the farthest distance	38397
@NP	the injury site -LRB- 19 mm -RRB-	38438
@NP	the injury site	38438
@NP	19 mm	38455
@NP	the highest functional scores of all of the lesioned rats	38466
@NP	the highest functional scores	38466
@NP	all of the lesioned rats	38499
@NP	all	38499
@NP	the lesioned rats	38506
@NP	This elongation	38525
@NP	ECs	38559
@NP	combination with MP	38588
@NP	combination	38588
@NP	MP	38605
@NP	more axons	38618
@NP	the MP/EC group	38643
@NP	the EC group at distances up to 13 mm caudal	38664
@NP	the EC group	38664
@NP	distances up to 13 mm caudal	38680
@NP	distances	38680
@NP	13 mm caudal	38696
@NP	the lesion	38712
@NP	this increase in axons	38724
@NP	this increase	38724
@NP	axons	38741
@NP	DFR performance of the MP/EC group	38787
@NP	DFR performance	38787
@NP	the MP/EC group	38806
@NP	78 %	38823
@NP	the EC group -LRB- 72 % -RRB-	38847
@NP	the EC group	38847
@NP	72 %	38861
@NP	more time	38882
@NP	it	38893
@NP	the larger number of axons seen at shorter distances	38913
@NP	the larger number	38913
@NP	axons seen at shorter distances	38934
@NP	axons	38934
@NP	shorter distances	38948
@NP	more functional recovery in the MP/EC group	39001
@NP	more functional recovery	39001
@NP	the MP/EC group	39029
@NP	It	39046
@NP	note	39072
@NP	MP	39091
@NP	combination	39106
@NP	ECs	39123
@NP	there	39128
@NP	a decrease	39142
@NP	axonal regeneration or functional recovery , which was a potential concern	39156
@NP	axonal regeneration or functional recovery	39156
@NP	a potential concern	39210
@NP	Astrocytes	39231
@NP	the capacity to act as immune cells -LRB- Dong and Benveniste , 2001 -RRB-	39247
@NP	immune cells -LRB- Dong and Benveniste , 2001 -RRB-	39270
@NP	immune cells	39270
@NP	Dong and Benveniste	39284
@NP	2001	39305
@NP	MP	39316
@NP	the function	39340
@NP	immune cells -LRB- Wahl et al. , 1975 ; Almawi et al. , 1991 -RRB-	39356
@NP	immune cells	39356
@NP	Wahl	39370
@NP	et al. , 1975 ; Almawi et al. , 1991	39375
@NP	et al.	39375
@NP	1975 ; Almawi et al.	39383
@NP	1975	39383
@NP	Almawi et al.	39389
@NP	Almawi	39389
@NP	et al.	39396
@NP	1991	39404
@NP	ECs	39419
@NP	phenotypic characteristics	39429
@NP	astrocytes	39461
@NP	it	39473
@NP	MP	39494
@NP	the function of ECs	39519
@NP	the function	39519
@NP	ECs	39535
@NP	a decreased effect in the MP/EC group	39553
@NP	a decreased effect	39553
@NP	the MP/EC group	39575
@NP	Investigation into the mechanisms of action of MP and ECs	39592
@NP	Investigation	39592
@NP	the mechanisms of action of MP and ECs	39611
@NP	the mechanisms	39611
@NP	action of MP and ECs	39629
@NP	action	39629
@NP	MP and ECs	39639
@NP	little insight	39656
@NP	the mechanism of action for MP	39695
@NP	the mechanism	39695
@NP	action for MP	39712
@NP	action	39712
@NP	MP	39723
@NP	the mechanism of action for ECs	39753
@NP	the mechanism	39753
@NP	action for ECs	39770
@NP	action	39770
@NP	ECs	39781
@NP	One mechanism to explain the action of MP	39820
@NP	One mechanism	39820
@NP	the action of MP	39845
@NP	the action	39845
@NP	MP	39859
@NP	binding	39873
@NP	the glucocorticoid receptor , which mediates its anti-inflammatory properties	39884
@NP	the glucocorticoid receptor	39884
@NP	its anti-inflammatory properties	39928
@NP	MP	39962
@NP	inflammatory processes	39974
@NP	SCI	40011
@NP	Hsu and Dimitrijevic	40016
@NP	1990	40038
@NP	chemotaxis -LRB- Espersen et al. , 1989 -RRB-	40053
@NP	chemotaxis	40053
@NP	Espersen	40065
@NP	et al. , 1989	40074
@NP	et al.	40074
@NP	1989	40082
@NP	the release of lysosomal enzymes -LRB- Schleimer et al. , 1989 -RRB-	40092
@NP	the release	40092
@NP	lysosomal enzymes -LRB- Schleimer et al. , 1989 -RRB-	40107
@NP	lysosomal enzymes	40107
@NP	Schleimer	40126
@NP	et al. , 1989	40136
@NP	et al.	40136
@NP	1989	40144
@NP	MP	40151
@NP	phospholipase A2 activity -LRB- Hirata et al. , 1980 -RRB-	40168
@NP	phospholipase A2 activity	40168
@NP	Hirata	40195
@NP	et al. , 1980	40202
@NP	et al.	40202
@NP	1980	40210
@NP	the production	40231
@NP	metabolites of the arachidonic acid cascade	40249
@NP	metabolites	40249
@NP	the arachidonic acid cascade	40264
@NP	Becker and Grasso	40294
@NP	1985	40313
@NP	the formation of free radicals	40336
@NP	the formation	40336
@NP	free radicals	40353
@NP	Hirata	40368
@NP	et al. , 1980	40375
@NP	et al.	40375
@NP	1980	40383
@NP	Becker and Grasso , 1985	40389
@NP	Becker and Grasso	40389
@NP	1985	40408
@NP	Kontos et al. , 1985	40414
@NP	Kontos	40414
@NP	et al. , 1985	40421
@NP	et al.	40421
@NP	1985	40429
@NP	Williams and Higgs , 1988	40435
@NP	Williams and Higgs	40435
@NP	1988	40455
@NP	MP	40462
@NP	expression of tumor necrosis factor aplha	40478
@NP	expression	40478
@NP	tumor necrosis factor aplha	40492
@NP	the activation of nuclear factor-kappaB -LRB- Xu et al. , 1998 -RRB-	40532
@NP	the activation	40532
@NP	nuclear factor-kappaB -LRB- Xu et al. , 1998 -RRB-	40550
@NP	nuclear factor-kappaB	40550
@NP	Xu	40573
@NP	et al. , 1998	40576
@NP	et al.	40576
@NP	1998	40584
@NP	the intensity and duration	40611
@NP	the inflammatory response -LRB- Xu et al. , 1998 -RRB-	40641
@NP	the inflammatory response	40641
@NP	Xu	40668
@NP	et al. , 1998	40671
@NP	et al.	40671
@NP	1998	40679
@NP	these effects	40694
@NP	administration of MP	40726
@NP	administration	40726
@NP	MP	40744
@NP	a dose of 0.03 mg/kg -LRB- Young et al. , 1988 -RRB-	40750
@NP	a dose	40750
@NP	0.03 mg/kg -LRB- Young et al. , 1988 -RRB-	40760
@NP	0.03 mg/kg	40760
@NP	Young	40772
@NP	et al. , 1988	40778
@NP	et al.	40778
@NP	1988	40786
@NP	SCI	40826
@NP	MP	40831
@NP	the large dose of 30 mg/kg -LRB- Hall et al. , 1984 -RRB-	40858
@NP	the large dose	40858
@NP	30 mg/kg -LRB- Hall et al. , 1984 -RRB-	40876
@NP	30 mg/kg	40876
@NP	Hall	40886
@NP	et al. , 1984	40891
@NP	et al.	40891
@NP	1984	40899
@NP	this dose	40909
@NP	MP	40920
@NP	antioxidant effects	40932
@NP	it	40966
@NP	free radicals	40981
@NP	the oxygen radical-induced lipid peroxidation	41012
@NP	cell membranes -LRB- Demopoulos et al. , 1980 -RRB-	41061
@NP	cell membranes	41061
@NP	Demopoulos	41077
@NP	et al. , 1980	41088
@NP	et al.	41088
@NP	1980	41096
@NP	This mechanism	41103
@NP	independent of the glucocorticoid receptor-mediated actions of MP	41136
@NP	independent of the glucocorticoid receptor-mediated actions	41136
@NP	the glucocorticoid	41151
@NP	MP	41199
@NP	the large dose required to achieve these effects -LRB- Hall et al. , 1984 -RRB-	41219
@NP	the large dose	41219
@NP	these effects -LRB- Hall et al. , 1984 -RRB-	41254
@NP	these effects	41254
@NP	Hall	41269
@NP	et al. , 1984	41274
@NP	et al.	41274
@NP	1984	41282
@NP	this theory	41305
@NP	data	41321
@NP	synthetic steroids	41345
@NP	greater antioxidant effects	41380
@NP	MP	41413
@NP	any glucocorticoid activity	41429
@NP	MP	41478
@NP	SCI -LRB- Hall , 1993 -RRB-	41500
@NP	SCI	41500
@NP	Hall	41505
@NP	1993	41511
@NP	The mechanism of action of ECs	41518
@NP	The mechanism	41518
@NP	action of ECs	41535
@NP	action	41535
@NP	ECs	41545
@NP	clues about the mechanism of action	41571
@NP	clues	41571
@NP	the mechanism of action	41583
@NP	the mechanism	41583
@NP	action	41600
@NP	ECs	41632
@NP	the growth of retinal ganglion neurites	41658
@NP	the growth	41658
@NP	retinal ganglion neurites	41672
@NP	coculture -LRB- Sonigra et al. , 1999 -RRB-	41701
@NP	coculture	41701
@NP	Sonigra	41712
@NP	et al. , 1999	41720
@NP	et al.	41720
@NP	1999	41728
@NP	that calciummediated signal transduction	41747
@NP	the growthpromoting properties of ECs , the calcium channel	41807
@NP	the growthpromoting properties	41807
@NP	ECs , the calcium channel	41841
@NP	ECs	41841
@NP	the calcium channel	41846
@NP	inhibitors verapamil and omega-conotoxin	41866
@NP	BAPTA-AM	41919
@NP	a calcium chelator	41929
@NP	the cocultures	41965
@NP	Application of these inhibitors	41981
@NP	Application	41981
@NP	these inhibitors	41996
@NP	the increase	42021
@NP	axonal growth	42037
@NP	the cocultures	42054
@NP	the conclusion	42081
@NP	ECs	42101
@NP	regeneration	42117
@NP	calcium-signaling pathways -LRB- Sonigra et al. , 1999 -RRB-	42138
@NP	calcium-signaling pathways	42138
@NP	Sonigra	42166
@NP	et al. , 1999	42174
@NP	et al.	42174
@NP	1999	42182
@NP	A subsequent study -LRB- Kafitz and Greer , 1999 -RRB-	42189
@NP	A subsequent study	42189
@NP	Kafitz and Greer , 1999	42209
@NP	Kafitz	42209
@NP	Greer , 1999	42220
@NP	Greer	42220
@NP	1999	42227
@NP	olfactory receptor cell extension in culture	42251
@NP	olfactory receptor cell extension	42251
@NP	culture	42288
@NP	exposure	42315
@NP	media conditioned by ECs	42327
@NP	media	42327
@NP	ECs	42348
@NP	the neurite growthpromoting properties of ECs	42369
@NP	the neurite growthpromoting properties	42369
@NP	ECs	42411
@NP	part	42433
@NP	diffusible factors	42451
@NP	Data supporting this idea	42471
@NP	Data	42471
@NP	this idea	42487
@NP	earlier this year	42510
@NP	ECs	42543
@NP	nerve growth factor	42569
@NP	brain-derived neurotrophic factor	42590
@NP	glial cell linederived neurotrophic factor -LRB- Woodhall et al. , 2001 -RRB-	42629
@NP	glial cell	42629
@NP	neurotrophic factor -LRB- Woodhall et al. , 2001 -RRB-	42652
@NP	neurotrophic factor	42652
@NP	Woodhall	42673
@NP	et al. , 2001	42682
@NP	et al.	42682
@NP	2001	42690
@NP	these data	42705
@NP	two mechanisms of action forMP and insights	42725
@NP	two mechanisms	42725
@NP	action forMP and insights	42743
@NP	possible mechanisms for ECs , what they did not provide	42774
@NP	possible mechanisms	42774
@NP	ECs , what they did not provide	42798
@NP	ECs	42798
@NP	they	42808
@NP	any insight into the effects of using MP and ECs in combination	42832
@NP	any insight	42832
@NP	the effects of using MP and ECs in combination	42849
@NP	the effects	42849
@NP	MP and ECs	42870
@NP	combination	42884
@NP	the study described in this paper	42906
@NP	the study	42906
@NP	this paper	42929
@NP	These experiments	42946
@NP	ECs , not only alone but also in combination with MP ,	42982
@NP	ECs	42982
@NP	combination with MP	43014
@NP	combination	43014
@NP	MP	43031
@NP	regrowth and extension of CST axons	43055
@NP	regrowth and extension	43055
@NP	CST axons	43081
@NP	trauma	43097
@NP	the adult rat spinal cord	43107
@NP	fact	43137
@NP	no statistical difference	43152
@NP	the EC and MP/EC groups	43196
@NP	a significant increase in axon numbers	43234
@NP	a significant increase	43234
@NP	axon numbers	43260
@NP	13 mm caudal to the lesion	43279
@NP	13 mm caudal	43279
@NP	the lesion	43295
@NP	MP	43320
@NP	the regenerative properties of ECs	43335
@NP	the regenerative properties	43335
@NP	ECs	43366
@NP	Results using ECs to repair damaged spinal cord axons in animal studies	43371
@NP	Results	43371
@NP	ECs	43385
@NP	damaged spinal cord axons	43399
@NP	animal studies	43428
@NP	researchers	43472
@NP	the feasibility of transplanting ECs into human beings	43517
@NP	the feasibility	43517
@NP	ECs	43550
@NP	human beings	43559
@NP	Pig ECs	43573
@NP	a human complement inhibitory protein	43624
@NP	rejection of the tissue	43693
@NP	rejection	43693
@NP	the tissue	43706
@NP	human beings -LRB- Imaizumi et al. , 2000 -RRB-	43738
@NP	human beings	43738
@NP	Imaizumi	43752
@NP	et al. , 2000	43761
@NP	et al.	43761
@NP	2000	43769
@NP	transplantation into adult rats after dorsal column transection	43782
@NP	transplantation	43782
@NP	adult rats after dorsal column transection	43803
@NP	adult rats	43803
@NP	dorsal column transection	43820
@NP	pig EC transplants	43847
@NP	axonal regeneration , elongation , and remyelination	43875
@NP	axonal regeneration	43875
@NP	elongation	43896
@NP	remyelination	43912
@NP	impulse conduction	43939
@NP	the lesion site -LRB- Imaizumi et al. , 2000 -RRB-	43965
@NP	the lesion site	43965
@NP	Imaizumi	43982
@NP	et al. , 2000	43991
@NP	et al.	43991
@NP	2000	43999
@NP	rodent and porcine ECs	44015
@NP	repair	44046
@NP	SCI	44059
@NP	little	44064
@NP	human ECs	44097
@NP	ECs	44118
@NP	adult human olfactory nerves	44137
@NP	patients undergoing olfactory nerve resection	44179
@NP	patients	44179
@NP	olfactory nerve resection	44199
@NP	the demyelinated spinal cords of adult rats -LRB- Kato et al. , 2000 -RRB-	44249
@NP	the	44249
@NP	spinal cords of adult rats -LRB- Kato et al. , 2000 -RRB-	44266
@NP	spinal cords	44266
@NP	adult rats -LRB- Kato et al. , 2000 -RRB-	44282
@NP	adult rats	44282
@NP	Kato	44294
@NP	et al. , 2000	44299
@NP	et al.	44299
@NP	2000	44307
@NP	Extensive remyelination , characteristic of ECs ,	44314
@NP	Extensive remyelination	44314
@NP	characteristic of ECs	44339
@NP	characteristic	44339
@NP	ECs	44357
@NP	the lesion site	44386
@NP	human ECs	44422
@NP	remyelination -LRB- Kato et al. , 2000 -RRB-	44452
@NP	remyelination	44452
@NP	Kato	44467
@NP	et al. , 2000	44472
@NP	et al.	44472
@NP	2000	44480
@NP	These results	44487
@NP	ECs	44526
@NP	good potential for treating spinal cord injuries in human beings	44535
@NP	good potential	44535
@NP	spinal cord injuries	44563
@NP	human beings	44587
@NP	The experiments described herein	44601
@NP	The experiments	44601
@NP	ECs	44647
@NP	axonal regeneration and elongation	44659
@NP	recovery of DFR behavior	44708
@NP	recovery	44708
@NP	DFR behavior	44720
@NP	SCI in adult rats	44739
@NP	SCI	44739
@NP	adult rats	44746
@NP	The morphological and functional regenerative properties of ECs	44758
@NP	The morphological and functional regenerative properties	44758
@NP	ECs	44818
@NP	combination	44853
@NP	MP	44870
@NP	the ability of ECs to promote axonal regeneration	44883
@NP	the ability	44883
@NP	ECs to promote axonal regeneration	44898
@NP	axonal regeneration	44913
@NP	13 mm caudal to the lesion	44956
@NP	13 mm caudal	44956
@NP	the lesion	44972
@NP	that ECs	44998
@NP	their regenerative properties	45019
@NP	combination	45062
@NP	MP	45079
@NP	another clinically relevant step	45091
@NP	the spinal cord injury problem	45139
@VP	fail to regenerate after spinal cord injury -LRB- SCI -RRB- in adult mammals	402
@VP	to regenerate after spinal cord injury -LRB- SCI -RRB- in adult mammals	407
@VP	regenerate after spinal cord injury -LRB- SCI -RRB- in adult mammals	410
@VP	leading to permanent loss	470
@VP	promotes neurological recovery in humans	611
@VP	combining ECs and MP after SCI	689
@VP	was investigated for the first time	720
@VP	investigated for the first time	724
@VP	lesioning the corticospinal tract in adult rats	763
@VP	were transplanted into the lesion	816
@VP	transplanted into the lesion	821
@VP	was administered for 24 hr	858
@VP	administered for 24 hr	862
@VP	reaching -LRB- DFR -RRB- , expressed as percentages	1000
@VP	expressed as percentages	1016
@VP	analyzed by counting the number of corticospinal axons	1066
@VP	counting the number of corticospinal axons	1078
@VP	anterogradely labeled with biotin dextran tetramethylrhodamine	1122
@VP	Lesioned control rats	1208
@VP	receiving either no treatment or vehicle	1231
@VP	had significantly more axons 7 mm caudal to the lesion	1398
@VP	was significantly improved -LRB- 57 % -RRB-	1474
@VP	improved -LRB- 57 % -RRB-	1492
@VP	received ECs in combination with MP	1518
@VP	had significantly more axons than all other lesioned rats up to 13 mm	1554
@VP	promote axonal regeneration and functional recovery after spinal cord lesions	1824
@VP	used in combination	1959
@VP	improve axonal regrowth up to 13 mm caudal to the lesion at 6 weeks after injury	1991
@VP	to regrow -LRB- Fawcett and Keynes , 1990 ; Raivich and Kreutzberg , 1993 -RRB-	2385
@VP	regrow -LRB- Fawcett and Keynes , 1990 ; Raivich and Kreutzberg , 1993 -RRB-	2388
@VP	to regenerate -LRB- Schwab and Bartholdi , 1996 ; Nicholls et al. , 1999 -RRB-	2476
@VP	regenerate -LRB- Schwab and Bartholdi , 1996 ; Nicholls et al. , 1999 -RRB-	2479
@VP	is found in the olfactory system	2561
@VP	found in the olfactory system	2564
@VP	have a life span of 4 weeks -LRB- Graziadei and Monti-Graziadei , 1978 -RRB-	2613
@VP	die	2690
@VP	reinnervate the olfactory bulb	2839
@VP	form functional synapses -LRB- Kosaka et al. , 1998 -RRB-	2874
@VP	termed olfactory ensheathing cells -LRB- ECs -RRB- -LRB- Doucette , 1984 -RRB-	3052
@VP	to promote regeneration in the olfactory system	3141
@VP	promote regeneration in the olfactory system	3144
@VP	to determine whether ECs retained their ability to promote regeneration	3255
@VP	determine whether ECs retained their ability to promote regeneration	3258
@VP	retained their ability to promote regeneration	3280
@VP	to promote regeneration	3303
@VP	promote regeneration	3306
@VP	reaching -LRB- DFR -RRB- , a measure of function -LRB- Li et al. , 1997 -RRB-	3715
@VP	using the same experimental model	3794
@VP	crossed the lesioned area	3888
@VP	reentered the spinal cord after transplantation of ECs into the injury site	3918
@VP	combined with injections of ECs	4057
@VP	transected spinal cords	4090
@VP	regenerated 2.5 cm -LRB- Ramon - Cueto et al. , 1998 -RRB-	4161
@VP	promote axonal regeneration	4237
@VP	is administration of methylprednisolone -LRB- MP -RRB-	4596
@VP	developed for its enhanced anti-inflammatory activity	4687
@VP	overcome by the production of an MP-hemisuccinated ester -LRB- Solu-Medrol -RRB-	4926
@VP	is injected into the body	5015
@VP	injected into the body	5018
@VP	is believed to cross the blood -- brain barrier -LRB- Hall , 1992 -RRB-	5116
@VP	believed to cross the blood -- brain barrier -LRB- Hall , 1992 -RRB-	5119
@VP	to cross the blood -- brain barrier -LRB- Hall , 1992 -RRB-	5128
@VP	cross the blood -- brain barrier -LRB- Hall , 1992 -RRB-	5131
@VP	to promote regeneration after SCI have been investigated	5746
@VP	promote regeneration after SCI have been investigated	5749
@VP	have been investigated	5780
@VP	been investigated	5785
@VP	investigated	5790
@VP	solve all of the problems associated with the lack of regeneration after SCI	5864
@VP	associated with the lack of regeneration after SCI	5890
@VP	shown to promote repair after SCI when used alone	5956
@VP	to promote repair after SCI when used alone	5962
@VP	promote repair after SCI when used alone	5965
@VP	used alone	5995
@VP	are ECs andMP	6006
@VP	combining MP administration with EC transplantation	6059
@VP	were used in this study	6427
@VP	used in this study	6432
@VP	were use to harvest ECs for transplants	6464
@VP	to harvest ECs for transplants	6473
@VP	harvest ECs for transplants	6476
@VP	were randomly placed into control and experimental groups	6517
@VP	placed into control and experimental groups	6531
@VP	did not survive beyond 14 d after surgery -LRB- n = 15 -RRB-	6648
@VP	survive beyond 14 d after surgery -LRB- n = 15 -RRB-	6656
@VP	failed to train in response to a food reward before surgery -LRB- n = 2 -RRB-	6707
@VP	to train in response to a food reward before surgery -LRB- n = 2 -RRB-	6714
@VP	train in response to a food reward before surgery -LRB- n = 2 -RRB-	6717
@VP	were anesthetized and decapitated	6909
@VP	decapitated	6931
@VP	were removed	6976
@VP	removed	6981
@VP	were detached	7035
@VP	detached	7040
@VP	were dissected , retained , triturated , and trypsinized	7106
@VP	dissected , retained , triturated , and trypsinized	7111
@VP	dissected	7111
@VP	retained , triturated ,	7122
@VP	trypsinized	7148
@VP	were centrifuged	7177
@VP	centrifuged	7182
@VP	was added to yield a suspension containing 8.5 x 10 5 cells/ml	7201
@VP	added to yield a suspension containing 8.5 x 10 5 cells/ml	7205
@VP	to yield a suspension containing 8.5 x 10 5 cells/ml	7211
@VP	yield a suspension containing 8.5 x 10 5 cells/ml	7214
@VP	containing 8.5 x 10 5 cells/ml	7233
@VP	seeded into an uncoated flask	7289
@VP	incubated -LRB- 48 hr , 37 °C and 5 % CO2 -RRB-	7323
@VP	remained in the supernatant	7502
@VP	had been found to be ≈ 93 % pure	7618
@VP	been found to be ≈ 93 % pure	7622
@VP	found to be ≈ 93 % pure	7627
@VP	to be ≈ 93 % pure	7633
@VP	be ≈ 93 % pure	7636
@VP	were randomly assigned to control or experimental groups	7831
@VP	assigned to control or experimental groups	7845
@VP	control	7857
@VP	follows	7922
@VP	follows	8020
@VP	to bend the cervical spinal cord for maximum exposure	8285
@VP	bend the cervical spinal cord for maximum exposure	8288
@VP	was performed exposing the dorsum of the spinal cord between C2 and C4	8354
@VP	performed exposing the dorsum of the spinal cord between C2 and C4	8358
@VP	exposing the dorsum of the spinal cord between C2 and C4	8368
@VP	were identified bilaterally	8445
@VP	identified bilaterally	8450
@VP	was passed through the spinal cord , isolating the dorsal funiculus	8543
@VP	passed through the spinal cord , isolating the dorsal funiculus	8547
@VP	isolating the dorsal funiculus	8579
@VP	was gently lifted	8629
@VP	gently lifted	8633
@VP	transect the dorsal funiculus , thereby transecting the dorsal CST	8706
@VP	transecting the dorsal CST	8745
@VP	confirmed accuracy of the lesion borders	8839
@VP	prelabeled with Cell	8885
@VP	were made just below the cut surface of the spinal cord	9078
@VP	made just below the cut surface of the spinal cord	9083
@VP	containing 50,000 ECs in DMEM -LRB- Biofluids , Rockville , MD -RRB-	9304
@VP	were administered consecutively over ≈ 2 min	9377
@VP	administered consecutively over ≈ 2 min	9382
@VP	receiving the vehicle for ECs	9427
@VP	were injected with an equal volume of DMEM into the CST	9457
@VP	injected with an equal volume of DMEM into the CST	9462
@VP	was placed in the lesion site -LRB- see Tracers below -RRB-	9608
@VP	placed in the lesion site -LRB- see Tracers below -RRB-	9612
@VP	see Tracers below	9639
@VP	were sutured	9690
@VP	sutured	9695
@VP	were placed on a heating pad to maintain body temperature	9717
@VP	placed on a heating pad to maintain body temperature	9722
@VP	to maintain body temperature	9746
@VP	maintain body temperature	9749
@VP	to alleviate pain	9911
@VP	alleviate pain	9914
@VP	was lesioned	9961
@VP	lesioned	9965
@VP	was administered via a tail vein	10088
@VP	administered via a tail vein	10092
@VP	receiving vehicle for MP	10243
@VP	underwent the same treatment regimen	10268
@VP	were injected with an equal volume of 0.09 % saline in a tail vein	10309
@VP	injected with an equal volume of 0.09 % saline in a tail vein	10314
@VP	returned	10516
@VP	see Surgical procedures	10550
@VP	to identify the neurons whose axons were transected	10638
@VP	identify the neurons whose axons were transected	10641
@VP	were transected	10674
@VP	transected	10679
@VP	confirming the lesion	10691
@VP	injected into the primary motor cortex	10874
@VP	was used to label CST axons caudal to the lesion site in the spinal cord	10914
@VP	used to label CST axons caudal to the lesion site in the spinal cord	10918
@VP	to label CST axons caudal to the lesion site in the spinal cord	10923
@VP	label CST axons caudal to the lesion site in the spinal cord	10926
@VP	caudal to the lesion site in the spinal cord	10942
@VP	were placed in a stereotaxic instrument	11032
@VP	placed in a stereotaxic instrument	11037
@VP	stereotaxically determined holes -LRB- 0.9 mm diameter -RRB-	11092
@VP	associated with the forelimbs	11201
@VP	follows : +0.5 AP and ± 3.5 ML ; +1.5 A/P and ± 2.5 ML ; and +2.5 AP and ±	11334
@VP	follows	11334
@VP	were delivered at a depth of 2.5 mm from the surface of the skull	11426
@VP	delivered at a depth of 2.5 mm from the surface of the skull	11431
@VP	was used to inject BDT bilaterally into layer V of the cortex	11518
@VP	used to inject BDT bilaterally into layer V of the cortex	11522
@VP	to inject BDT bilaterally into layer V of the cortex	11527
@VP	inject BDT bilaterally into layer V of the cortex	11530
@VP	were used to administer a total of 1.2 µl of the anterograde tracer	11628
@VP	used to administer a total of 1.2 µl of the anterograde tracer	11633
@VP	to administer a total of 1.2 µl of the anterograde tracer	11638
@VP	administer a total of 1.2 µl of the anterograde tracer	11641
@VP	was used to seal the holes in the skull	11732
@VP	used to seal the holes in the skull	11736
@VP	to seal the holes in the skull	11741
@VP	seal the holes in the skull	11744
@VP	was sutured	11783
@VP	sutured	11787
@VP	was administered immediately after surgery to alleviate pain	11843
@VP	administered immediately after surgery to alleviate pain	11847
@VP	to alleviate pain	11886
@VP	alleviate pain	11889
@VP	were killed 3 d after tracer injections	11910
@VP	killed 3 d after tracer injections	11915
@VP	modified version of an apparatus -LRB- Castro , 1972 -RRB- designed to test DFR	11982
@VP	designed to test DFR	12030
@VP	to test DFR	12039
@VP	test DFR	12042
@VP	was used to measure grasping ability -LRB- Fig. 1A , B -RRB-	12051
@VP	used to measure grasping ability -LRB- Fig. 1A , B -RRB-	12055
@VP	to measure grasping ability -LRB- Fig. 1A , B -RRB-	12060
@VP	measure grasping ability -LRB- Fig. 1A , B -RRB-	12063
@VP	grasping ability -LRB- Fig. 1A , B -RRB-	12071
@VP	was a box with two compartments separated by a Plexiglas divider	12115
@VP	separated by a Plexiglas divider	12147
@VP	subdivided into 14 adjacent slots of equal size -LRB- 2 x 1.25 x 3 inches -RRB-	12347
@VP	was made of a movable shelf	12453
@VP	made of a movable shelf	12457
@VP	pulled back to produce a 0.75 inch opening in the floor between the compartments	12504
@VP	to produce a 0.75 inch opening in the floor between the compartments	12516
@VP	produce a 0.75 inch opening in the floor between the compartments	12519
@VP	see Testing procedures	12609
@VP	to produce a continuous floor between the two compartments	12633
@VP	produce a continuous floor between the two compartments	12636
@VP	was performed with the three-quarter inch opening in the floor	12734
@VP	performed with the three-quarter inch opening in the floor	12738
@VP	separating the rat compartment from the food compartment	12846
@VP	was placed into each of the 14 slots in the minor compartment	13051
@VP	placed into each of the 14 slots in the minor compartment	13055
@VP	to grasp a food pellet	13201
@VP	grasp a food pellet	13204
@VP	could use either forelimb to retrieve the food pellet	13234
@VP	use either forelimb to retrieve the food pellet	13240
@VP	to retrieve the food pellet	13260
@VP	retrieve the food pellet	13263
@VP	were only large enough to admit one limb at a time	13328
@VP	to admit one limb at a time	13351
@VP	admit one limb at a time	13354
@VP	ensured that the rats grasped and lifted the food pellet to retrieve it	13405
@VP	grasped and lifted the food pellet to retrieve it	13427
@VP	grasped	13427
@VP	lifted the food pellet to retrieve it	13439
@VP	to retrieve it	13462
@VP	retrieve it	13465
@VP	to scoop or rake a pellet out of the slot without grasping and lifting it	13497
@VP	scoop or rake a pellet out of the slot without grasping and lifting it	13500
@VP	grasping and lifting it	13547
@VP	would fall irretrievably through the opening in the floor	13583
@VP	fall irretrievably through the opening in the floor	13589
@VP	Testing procedures Before surger y.	13642
@VP	were reduced to no less than 80 % of heir original body weight at any time	13839
@VP	reduced to no less than 80 % of heir original body weight at any time	13844
@VP	to learn the task while they became familiar with the testing situation	13985
@VP	learn the task while they became familiar with the testing situation	13988
@VP	became familiar with the testing situation	14014
@VP	was initially raised 1 inch above the floor	14110
@VP	initially raised 1 inch above the floor	14114
@VP	then lowered to 0.25 inches	14155
@VP	positioned flush against the floor	14193
@VP	were trained and tested at this most stringent level	14238
@VP	trained and tested at this most stringent level	14243
@VP	was created that disrupted grasping in both paws	14554
@VP	created that disrupted grasping in both paws	14558
@VP	disrupted grasping in both paws	14571
@VP	grasping in both paws	14581
@VP	was not collected	14638
@VP	collected	14646
@VP	were trained twice per day for 5 d and then tested twice per day for 5 d	14665
@VP	trained twice per day for 5 d and then tested twice per day for 5 d	14670
@VP	trained twice per day for 5 d	14670
@VP	tested twice per day for 5 d	14709
@VP	were collected	14764
@VP	collected	14769
@VP	were given 5 min to complete the task	14812
@VP	given 5 min to complete the task	14817
@VP	to complete the task	14829
@VP	complete the task	14832
@VP	were allowed to make as many attempts as they wanted during this time period	14854
@VP	allowed to make as many attempts as they wanted during this time period	14859
@VP	to make as many attempts as they wanted during this time period	14867
@VP	make as many attempts as they wanted during this time period	14870
@VP	wanted during this time period	14900
@VP	to ensure that they were healthy before undergoing surgery	15002
@VP	ensure that they were healthy before undergoing surgery	15005
@VP	were healthy before undergoing surgery	15022
@VP	undergoing surgery	15042
@VP	were trained twice per week during weeks 2 -- 5 after surgery	15083
@VP	trained twice per week during weeks 2 -- 5 after surgery	15088
@VP	to perform the grasping portion of the DFR task in the early postsurgical period	15198
@VP	perform the grasping portion of the DFR task in the early postsurgical period	15201
@VP	were therefore completely unable	15283
@VP	to retrieve the food reward	15316
@VP	retrieve the food reward	15319
@VP	to allow the food to be raked into the main compartment	15414
@VP	allow the food to be raked into the main compartment	15417
@VP	to be raked into the main compartment	15432
@VP	be raked into the main compartment	15435
@VP	raked into the main compartment	15438
@VP	ensuring that the reaching portion of the DFR task did not extinguish	15471
@VP	did not extinguish	15522
@VP	extinguish	15530
@VP	decreased as the postsurgical period increased	15582
@VP	increased	15619
@VP	was gradually reestablished	15659
@VP	gradually reestablished	15663
@VP	were tested twice per day for 5 d	15910
@VP	tested twice per day for 5 d	15915
@VP	were collected by a blinded investigator	15971
@VP	collected by a blinded investigator	15976
@VP	were allowed 5 min to complete the task during the postsurgery testing period	16068
@VP	allowed 5 min to complete the task during the postsurgery testing period	16073
@VP	to complete the task during the postsurgery testing period	16087
@VP	complete the task during the postsurgery testing period	16090
@VP	were allowed to make as many attempts as they wanted during this time period	16150
@VP	allowed to make as many attempts as they wanted during this time period	16155
@VP	to make as many attempts as they wanted during this time period	16163
@VP	make as many attempts as they wanted during this time period	16166
@VP	wanted during this time period	16196
@VP	was scored only when a rat reached into a slot and displaced the pellet	16340
@VP	scored only when a rat reached into a slot and displaced the pellet	16344
@VP	reached into a slot and displaced the pellet	16367
@VP	reached into a slot	16367
@VP	displaced the pellet	16391
@VP	dropped it through the gap in the floor	16415
@VP	grasped a pellet	16500
@VP	lifted it over the gap in the floor	16518
@VP	was in the main portion of the testing apparatus	16613
@VP	was used to reduce arbitrariness by the investigator	16700
@VP	used to reduce arbitrariness by the investigator	16704
@VP	to reduce arbitrariness by the investigator	16709
@VP	reduce arbitrariness by the investigator	16712
@VP	was important for interpretation of the data	16757
@VP	were analyzed using the statistical software program Prism	16808
@VP	analyzed using the statistical software program Prism	16813
@VP	using the statistical software program Prism	16822
@VP	are presented as mean ± SEM percentages	16986
@VP	presented as mean ± SEM percentages	16990
@VP	lesioning	17063
@VP	were anesthetized with chloral hydrate -LRB- 10 ml/kg ; Sigma , St.	17079
@VP	followed by 300 ml of 4 % paraformaldehyde in 0.1 M phosphate buffer	17207
@VP	were killed	17294
@VP	killed	17299
@VP	were cut coronally	17433
@VP	cut coronally	17438
@VP	cut horizontally at a thickness of 20 µm with a freezing microtome	17478
@VP	mounted on ProbeOn -LRB- Fisher Scientific , Pittsburgh , PA -RRB-	17549
@VP	were captured using a Sony -LRB- Tokyo , Japan -RRB-	17737
@VP	captured using a Sony -LRB- Tokyo , Japan -RRB-	17742
@VP	using a Sony -LRB- Tokyo , Japan -RRB-	17751
@VP	was identified based on the stereotaxic BDT injection sites	17874
@VP	identified based on the stereotaxic BDT injection sites	17878
@VP	is taken up by cut axons but not intact axons	18096
@VP	taken up by cut axons but not intact axons	18099
@VP	was examined	18194
@VP	examined	18198
@VP	occupying the region of the spinal cord normally occupied by the dorsal CST	18234
@VP	were counted	18310
@VP	counted	18315
@VP	consulting with a biomedical statistician	18330
@VP	would result in a precision of X ± 5.4 axons	18484
@VP	result in a precision of X ± 5.4 axons	18490
@VP	to begin counts	18556
@VP	begin counts	18559
@VP	was determined by randomly selecting a number between 1 and 4	18572
@VP	determined by randomly selecting a number between 1 and 4	18576
@VP	selecting a number between 1 and 4	18599
@VP	beginning 1 mm distal to the injury -LRB- i.e. , 1 mm , 4 mm , 7 mm , etc. -RRB-	18737
@VP	ending 19 mm caudal to the lesion site	18808
@VP	extends to T1 , a distance of 15.1 mm from the lesion at C3	18879
@VP	representing the forepaw	19039
@VP	was examined	19064
@VP	examined	19068
@VP	combined	19154
@VP	was counted	19215
@VP	counted	19219
@VP	counted	19242
@VP	traversed out of the focal plane and reemerged farther down in the same field	19361
@VP	traversed out of the focal plane	19361
@VP	reemerged farther down in the same field	19398
@VP	were compiled	19455
@VP	compiled	19460
@VP	were analyzed using the statistical software program Prism	19475
@VP	analyzed using the statistical software program Prism	19480
@VP	using the statistical software program Prism	19489
@VP	counted	19700
@VP	are presented as mean ± SEM number of axons	19714
@VP	presented as mean ± SEM number of axons	19718
@VP	viewed from the front , with the opening in the floor at 0.75 inches	19859
@VP	represent food pellets used as a reward	19940
@VP	used as a reward	19963
@VP	was used for all testing procedures	20071
@VP	used for all testing procedures	20075
@VP	expressed as percentages of total attempts	20169
@VP	tested before surgery	20218
@VP	was required for inclusion in the study	20244
@VP	required for inclusion in the study	20248
@VP	performed the DFR task successfully at least 90 % of the trials	20315
@VP	expressed as percentages of total attempts	20438
@VP	performed significantly better than all of the other groups	20514
@VP	performed significantly worse than the MP group -LRB- 56.66 ± 5.63 % -RRB-	20711
@VP	performed the DFR task significantly better than all other lesioned animals	20869
@VP	were not significantly different from each other	20972
@VP	filled with the retrograde tracer Fluorogold	21080
@VP	were severed in the spinal cord at C3	21173
@VP	severed in the spinal cord at C3	21178
@VP	can be seen filling the soma , axons , and dendrites of these neurons	21223
@VP	be seen filling the soma , axons , and dendrites of these neurons	21227
@VP	seen filling the soma , axons , and dendrites of these neurons	21230
@VP	filling the soma , axons , and dendrites of these neurons	21235
@VP	are red because they are labeled with BDT	21529
@VP	are labeled with BDT	21550
@VP	labeled with BDT	21554
@VP	are significantly more axons in the MP group -LRB- G ; 32.01 ± 3.41 -RRB-	21745
@VP	has significantly more axons than the MP group	21840
@VP	has significantly more axons than all other lesioned groups	21926
@VP	is no significant -LRB- Figure legend continues	22016
@VP	continues	22049
@VP	continued	22076
@VP	have significantly fewer axons than the EC group -LRB- K ; 12.35 ± 2.57 -RRB-	22338
@VP	has significantly fewer axons than the MP/EC group -LRB- N ; 22.48 ± 6.00 -RRB-	22423
@VP	are still not statistically different	22706
@VP	have significantly more axons than all other lesioned groups	22803
@VP	is no significant difference between these groups	22875
@VP	are so high at all distances relative to the axon means for the other groups	23280
@VP	relative to the axon means for the other groups	23309
@VP	are only presented graphically at 1 mm caudal to the lesion -LRB- A -RRB-	23386
@VP	presented graphically at 1 mm caudal to the lesion -LRB- A -RRB-	23395
@VP	used in this study	23662
@VP	are presented as mean ± SEM number of axons	23687
@VP	presented as mean ± SEM number of axons	23691
@VP	colocalized with axons	23747
@VP	surrounded by Cell Tracker green-labeled ECs	23818
@VP	were at all distances	23900
@VP	analyzed	24070
@VP	observed for lack of bladder control , wound opening , and signs of infection	24184
@VP	were not systematically analyzed for neurological deficits	24264
@VP	analyzed for neurological deficits	24288
@VP	was noted	24372
@VP	noted	24376
@VP	resolved within 2 weeks of surgery	24402
@VP	were tested before surgery to establish a DFR presurgery baseline	24463
@VP	tested before surgery to establish a DFR presurgery baseline	24468
@VP	to establish a DFR presurgery baseline	24490
@VP	establish a DFR presurgery baseline	24493
@VP	were functionally capable of performing the DFR task before lesioning	24578
@VP	performing the DFR task before lesioning	24607
@VP	lesioning	24638
@VP	influencing the postsurgical scores	24700
@VP	were required to perform the DFR task at a success rate of at least 90 %	24746
@VP	required to perform the DFR task at a success rate of at least 90 %	24751
@VP	to perform the DFR task at a success rate of at least 90 %	24760
@VP	perform the DFR task at a success rate of at least 90 %	24763
@VP	noted at the beginning of Materials and Methods	24822
@VP	did not perform at this level and were therefore eliminated from the study	24880
@VP	did not perform at this level	24880
@VP	perform at this level	24888
@VP	were therefore eliminated from the study	24914
@VP	therefore eliminated from the study	24919
@VP	met the criterion necessary for inclusion in the study	24971
@VP	follows	25086
@VP	were tested to assess their ability to perform the DFR task -LRB- Fig. 1D -RRB-	25262
@VP	tested to assess their ability to perform the DFR task -LRB- Fig. 1D -RRB-	25267
@VP	to assess their ability to perform the DFR task -LRB- Fig. 1D -RRB-	25274
@VP	assess their ability to perform the DFR task -LRB- Fig. 1D -RRB-	25277
@VP	to perform the DFR task -LRB- Fig. 1D -RRB-	25298
@VP	perform the DFR task -LRB- Fig. 1D -RRB-	25301
@VP	Using this functional test	25333
@VP	did presurgically	25448
@VP	inhibited the rats ' abilities to perform the DFR task	25563
@VP	to perform the DFR task	25593
@VP	perform the DFR task	25596
@VP	was noted in all rats that were lesioned	25686
@VP	noted in all rats that were lesioned	25690
@VP	were lesioned	25713
@VP	lesioned	25718
@VP	performing the DFR task	25801
@VP	was not the same across all of the experimental groups	25825
@VP	were the most impaired of all of the groups after surgery	25911
@VP	was no significant difference between these two groups	26114
@VP	performed significantly better than the lesion and vehicle groups	26222
@VP	received the combination treatment of ECs and MP	26608
@VP	received ECs alone	26736
@VP	was not statistically significant	26781
@VP	was examined in all rats used in this study	26896
@VP	examined in all rats used in this study	26900
@VP	used in this study	26921
@VP	were transected during the lesioning procedure -LRB- Fig. 2 -RRB-	27073
@VP	transected during the lesioning procedure -LRB- Fig. 2 -RRB-	27078
@VP	were transected during surgery and not just those in the forelimb representation	27184
@VP	transected during surgery	27189
@VP	were found throughout the primary motor cortex in layer V.	27293
@VP	found throughout the primary motor cortex in layer V.	27298
@VP	were also found scattered throughout the primary motor cortex in layer V.	27380
@VP	found scattered throughout the primary motor cortex in layer V.	27390
@VP	scattered throughout the primary motor cortex in layer V.	27396
@VP	were in the sham group , whose brains had no Fluorogold label	27654
@VP	had no Fluorogold label	27691
@VP	was not necessarily found in all of the animals in every group	27854
@VP	necessarily found in all of the animals in every group	27862
@VP	did not have any BDT-labeled CST axons caudal to the lesion site	27974
@VP	have any BDT-labeled CST axons caudal to the lesion site	27982
@VP	caudal to the lesion site	28013
@VP	did not result from a problem with the BDT or the labeling technique	28085
@VP	result from a problem with the BDT or the labeling technique	28093
@VP	were examined rostral to the lesion	28192
@VP	examined rostral to the lesion	28197
@VP	were found to have BDT-labeled CST axons proximal to the injury site	28239
@VP	found to have BDT-labeled CST axons proximal to the injury site	28244
@VP	to have BDT-labeled CST axons proximal to the injury site	28250
@VP	have BDT-labeled CST axons proximal to the injury site	28253
@VP	found to course in the white matter of the dorsal funiculus	28339
@VP	were seen to enter the gray matter	28417
@VP	seen to enter the gray matter	28422
@VP	to enter the gray matter	28427
@VP	enter the gray matter	28430
@VP	did migrate into the gray matter	28474
@VP	migrate into the gray matter	28478
@VP	coursed along the border between the gray and white matter	28513
@VP	received EC transplants	28592
@VP	were found to migrate throughout the spinal cord white matter	28621
@VP	found to migrate throughout the spinal cord white matter	28626
@VP	to migrate throughout the spinal cord white matter	28632
@VP	migrate throughout the spinal cord white matter	28635
@VP	were rarely found in the spinal cord gray matter	28698
@VP	found in the spinal cord gray matter	28710
@VP	were not found to specifically align along the length of the axons	28765
@VP	found to specifically align along the length of the axons	28774
@VP	to specifically align along the length of the axons	28780
@VP	specifically align along the length of the axons	28783
@VP	were found in all areas in which regrowing axons were seen	28841
@VP	found in all areas in which regrowing axons were seen	28846
@VP	were seen	28890
@VP	seen	28895
@VP	was analyzed up to 19 mm caudal to the lesion	28912
@VP	analyzed up to 19 mm caudal to the lesion	28916
@VP	to be similar to all distances analyzed at 4 mm caudal to the lesion and beyond	29039
@VP	be similar to all distances analyzed at 4 mm caudal to the lesion and beyond	29042
@VP	analyzed at 4 mm caudal to the lesion and beyond	29070
@VP	did appear to be most dense at 1 mm caudal to the lesion	29133
@VP	appear to be most dense at 1 mm caudal to the lesion	29137
@VP	to be most dense at 1 mm caudal to the lesion	29144
@VP	be most dense at 1 mm caudal to the lesion	29147
@VP	comparing the means from the groups -LRB- Fig. 4A -- C -RRB-	29415
@VP	are presented for 1 , 10 , and 19 mm	29463
@VP	presented for 1 , 10 , and 19 mm	29467
@VP	Presented in Figure 4D	29499
@VP	labeled axons for each group at all of the distances examined	29544
@VP	examined	29597
@VP	were much larger than the means of all the other groups , except at 1 mm	29773
@VP	presents the data for the groups at 1 mm caudal to the lesion	29938
@VP	examined intervals	30023
@VP	were highest in the sham group -LRB- Fig. 4D -RRB-	30068
@VP	examined	30132
@VP	is noted below	30270
@VP	noted below	30273
@VP	Supporting the functional data reported above	30286
@VP	reported above	30317
@VP	examined	30436
@VP	were found only a short distance caudal to the injury -LRB- Fig. 4A -RRB-	30482
@VP	found only a short distance caudal to the injury -LRB- Fig. 4A -RRB-	30487
@VP	examined	30617
@VP	could be found through 7 mm	30781
@VP	be found through 7 mm	30787
@VP	found through 7 mm	30790
@VP	had very few labeled axons -LRB- Figs. 3G -- I , 4D -RRB-	30847
@VP	labeled axons -LRB- Figs. 3G -- I , 4D -RRB-	30860
@VP	analyzed statistically	30897
@VP	were found among the means of these three groups -LRB- Fig. 4B -- D -RRB-	31091
@VP	found among the means of these three groups -LRB- Fig. 4B -- D -RRB-	31096
@VP	decreases in proportion to distance caudal to the injury -LRB- Fig. 4D -RRB-	31404
@VP	were visible even at the farthest distance analyzed -LRB- Fig. 3L -RRB-	31478
@VP	analyzed -LRB- Fig. 3L -RRB-	31521
@VP	examined in the EC group	31555
@VP	were found in the areas in which regrowing axons were located -LRB- Fig. 5 -RRB-	31611
@VP	found in the areas in which regrowing axons were located -LRB- Fig. 5 -RRB-	31616
@VP	were located	31660
@VP	had significantly more axons at all distances examined -LRB- Fig. 4 -RRB-	31786
@VP	examined -LRB- Fig. 4 -RRB-	31832
@VP	receiving ECs	31928
@VP	had significantly more axons than the MP/EC group -LRB- Figs. 3M -- R , 4 -RRB-	32200
@VP	decreased as distance from the lesion increased -LRB- Fig. 3M -- O , 4D -RRB-	32336
@VP	increased -LRB- Fig. 3M -- O , 4D -RRB-	32374
@VP	could still be seen at 19 mm -LRB- Fig. 3O -RRB-	32411
@VP	be seen at 19 mm -LRB- Fig. 3O -RRB-	32423
@VP	seen at 19 mm -LRB- Fig. 3O -RRB-	32426
@VP	were visible throughout the regions in which axons were found -LRB- Fig. 5 -RRB-	32506
@VP	were found	32557
@VP	found	32562
@VP	examined	32715
@VP	agrees with the functional findings presented above	32740
@VP	presented above	32776
@VP	received only ECs , significant differences in results	32909
@VP	occurred at most distances	32963
@VP	caudal to the injury -LRB- Fig. 4 -RRB-	32990
@VP	had significantly more axons than the EC group -LRB- Fig. 4A , B , D -RRB-	33104
@VP	were found at 16 and 19 mm caudal to the lesion -LRB- Fig. 4C , D -RRB-	33240
@VP	found at 16 and 19 mm caudal to the lesion -LRB- Fig. 4C , D -RRB-	33245
@VP	analyzed	33409
@VP	may have resulted in functional differences with a longer recovery period	33519
@VP	have resulted in functional differences with a longer recovery period	33523
@VP	resulted in functional differences with a longer recovery period	33528
@VP	to restore sensory and motor function after debilitating SCI in humans	33657
@VP	restore sensory and motor function after debilitating SCI in humans	33660
@VP	debilitating SCI in humans	33701
@VP	is being made in animal research	33747
@VP	being made in animal research	33750
@VP	made in animal research	33756
@VP	are	34173
@VP	must be resolved before its use in a clinical setting	35059
@VP	be resolved before its use in a clinical setting	35064
@VP	resolved before its use in a clinical setting	35067
@VP	have also been shown to promote regeneration after SCI	35128
@VP	been shown to promote regeneration after SCI	35138
@VP	shown to promote regeneration after SCI	35143
@VP	to promote regeneration after SCI	35149
@VP	promote regeneration after SCI	35152
@VP	resulting in reduced gliosis	35282
@VP	improved Schwann cell survival	35312
@VP	improved regeneration of axons -LRB- Martin et al. , 1996 -RRB-	35348
@VP	Transplanted	35402
@VP	produce modest functional improvement -LRB- Guest et al. , 1997 -RRB-	35665
@VP	encourage axonal regrowth and improve function	35761
@VP	encourage axonal regrowth	35761
@VP	improve function	35791
@VP	do not thrive well in the CNS	35823
@VP	thrive well in the CNS	35830
@VP	have a poor survivability rate in the presence of astrocytes	35906
@VP	is diminished -LRB- Franklin and Blakemore , 1993 ; Iwaniuk et al. , 1999 -RRB-	36001
@VP	diminished -LRB- Franklin and Blakemore , 1993 ; Iwaniuk et al. , 1999 -RRB-	36004
@VP	is much more prevalent -LRB- Duncan et al. , 1988 ; Shields et al. , 2000 -RRB-	36130
@VP	transplanted into the CNS	36238
@VP	are capable of promoting CNS axon regeneration	36264
@VP	promoting CNS axon regeneration	36279
@VP	endogenously exists in the CNS	36497
@VP	thrive in the CNS environment	36553
@VP	promote regeneration and remyelination	36595
@VP	meets these criteria	36652
@VP	shown recently to promote regeneration after SCI	36792
@VP	to promote regeneration after SCI	36807
@VP	promote regeneration after SCI	36810
@VP	has been reported previously regarding the ability of ECs	37062
@VP	been reported previously regarding the ability of ECs	37066
@VP	reported previously regarding the ability of ECs	37071
@VP	to promote axonal regeneration and functional recovery	37120
@VP	promote axonal regeneration and functional recovery	37123
@VP	promoted the regrowth of CST axons grown through the lesioned site	37288
@VP	grown through the lesioned site	37323
@VP	Transplanted ECs	37356
@VP	have also been reported previously to promote functional	37373
@VP	been reported previously to promote functional	37383
@VP	reported previously to promote functional	37388
@VP	to promote functional	37408
@VP	promote functional	37411
@VP	supports	37509
@VP	combined with other therapies	37574
@VP	has also been investigated	37604
@VP	been investigated	37613
@VP	investigated	37618
@VP	had investigated ECs in combination with MP	37671
@VP	investigated ECs in combination with MP	37675
@VP	described herein	37971
@VP	promote axonal regeneration	38004
@VP	improve functional recovery after SCI when compared with untreated rats	38036
@VP	compared with untreated rats	38079
@VP	to result in complete restoration of DFR function -LRB- 57 % -RRB-	38185
@VP	result in complete restoration of DFR function -LRB- 57 % -RRB-	38188
@VP	resulting from the limited distance that axons	38251
@VP	axons	38292
@VP	were found to regenerate -LRB- ≈ 7 mm -RRB-	38298
@VP	found to regenerate -LRB- ≈ 7 mm -RRB-	38303
@VP	to regenerate -LRB- ≈ 7 mm -RRB-	38309
@VP	regenerate -LRB- ≈ 7 mm -RRB-	38312
@VP	was found whether ECs were applied alone or in combination with MP	38541
@VP	found whether ECs were applied alone or in combination with MP	38545
@VP	were applied alone or in combination with MP	38563
@VP	applied alone or in combination with MP	38568
@VP	compared with the EC group -LRB- 72 % -RRB-	38833
@VP	seen at shorter distances	38940
@VP	could extend farther , resulting in more functional recovery in the MP/EC group	38966
@VP	extend farther , resulting in more functional recovery in the MP/EC group	38972
@VP	resulting in more functional recovery in the MP/EC group	38988
@VP	was used in combination with ECs	39094
@VP	used in combination with ECs	39098
@VP	was a potential concern	39206
@VP	have the capacity to act as immune cells -LRB- Dong and Benveniste , 2001 -RRB-	39242
@VP	to act as immune cells -LRB- Dong and Benveniste , 2001 -RRB-	39260
@VP	act as immune cells -LRB- Dong and Benveniste , 2001 -RRB-	39263
@VP	share phenotypic characteristics with astrocytes	39423
@VP	resulting in a decreased effect in the MP/EC group	39540
@VP	seen below	39683
@VP	is still hotly debated	39726
@VP	hotly debated	39735
@VP	is just starting to be elucidated	39785
@VP	starting to be elucidated	39793
@VP	to be elucidated	39802
@VP	be elucidated	39805
@VP	elucidated	39808
@VP	to explain the action of MP	39834
@VP	explain the action of MP	39837
@VP	mediates its anti-inflammatory properties	39919
@VP	thereby reducing the formation of free radicals	40319
@VP	decreasing the activation of nuclear factor-kappaB -LRB- Xu et al. , 1998 -RRB-	40521
@VP	to be clinically effective after SCI	40793
@VP	be clinically effective after SCI	40796
@VP	be administered at the large dose of 30 mg/kg -LRB- Hall et al. , 1984 -RRB-	40839
@VP	administered at the large dose of 30 mg/kg -LRB- Hall et al. , 1984 -RRB-	40842
@VP	required to achieve these effects -LRB- Hall et al. , 1984 -RRB-	41234
@VP	to achieve these effects -LRB- Hall et al. , 1984 -RRB-	41243
@VP	achieve these effects -LRB- Hall et al. , 1984 -RRB-	41246
@VP	created to have greater antioxidant effects than MP	41364
@VP	to have greater antioxidant effects than MP	41372
@VP	have greater antioxidant effects than MP	41375
@VP	lacking any glucocorticoid activity	41421
@VP	are as effective as MP when applied after SCI -LRB- Hall , 1993 -RRB-	41458
@VP	applied after SCI -LRB- Hall , 1993 -RRB-	41486
@VP	is still unknown	41549
@VP	are beginning to emerge	41607
@VP	beginning to emerge	41611
@VP	to emerge	41621
@VP	emerge	41624
@VP	may be involved in the growthpromoting properties of ECs , the calcium channel	41788
@VP	be involved in the growthpromoting properties of ECs , the calcium channel	41792
@VP	involved in the growthpromoting properties of ECs , the calcium channel	41795
@VP	were applied to the cocultures	41949
@VP	applied to the cocultures	41954
@VP	was facilitated by exposure to media conditioned by ECs	42296
@VP	facilitated by exposure to media conditioned by ECs	42300
@VP	conditioned by ECs	42333
@VP	were , at least in part , mediated by diffusible factors	42415
@VP	mediated by diffusible factors	42439
@VP	supporting this idea	42476
@VP	cultured ECs	42534
@VP	linederived neurotrophic factor -LRB- Woodhall et al. , 2001 -RRB-	42640
@VP	did not provide	42813
@VP	provide	42821
@VP	is any insight into the effects of using MP and ECs in combination	42829
@VP	using MP and ECs in combination	42864
@VP	described in this paper	42916
@VP	does	42940
@VP	was found between the EC and MP/EC groups functionally	43178
@VP	found between the EC and MP/EC groups functionally	43182
@VP	may improve the regenerative properties of ECs	43323
@VP	improve the regenerative properties of ECs	43327
@VP	using ECs to repair damaged spinal cord axons in animal studies	43379
@VP	to repair damaged spinal cord axons in animal studies	43389
@VP	repair damaged spinal cord axons in animal studies	43392
@VP	beginning to investigate the feasibility of transplanting ECs into human beings	43492
@VP	to investigate the feasibility of transplanting ECs into human beings	43502
@VP	investigate the feasibility of transplanting ECs into human beings	43505
@VP	transplanting ECs into human beings	43536
@VP	is intended to decrease rejection of the tissue	43669
@VP	intended to decrease rejection of the tissue	43672
@VP	to decrease rejection of the tissue	43681
@VP	decrease rejection of the tissue	43684
@VP	transplanted into human beings -LRB- Imaizumi et al. , 2000 -RRB-	43720
@VP	promoted axonal regeneration , elongation , and remyelination	43866
@VP	promote repair after SCI	44038
@VP	has been determined about human ECs	44071
@VP	been determined about human ECs	44075
@VP	determined about human ECs	44080
@VP	removed from patients undergoing olfactory nerve resection	44166
@VP	undergoing olfactory nerve resection	44188
@VP	demyelinated spinal cords of adult rats -LRB- Kato et al. , 2000 -RRB-	44253
@VP	are able to promote remyelination -LRB- Kato et al. , 2000 -RRB-	44432
@VP	to promote remyelination -LRB- Kato et al. , 2000 -RRB-	44441
@VP	promote remyelination -LRB- Kato et al. , 2000 -RRB-	44444
@VP	have good potential for treating spinal cord injuries in human beings	44530
@VP	treating spinal cord injuries in human beings	44554
@VP	described herein	44617
@VP	resulting in recovery of DFR behavior after SCI in adult rats	44695
@VP	were not hindered when used in combination with MP	44822
@VP	hindered when used in combination with MP	44831
@VP	used in combination with MP	44845
@VP	to promote axonal regeneration	44902
@VP	promote axonal regeneration	44905
@VP	was enhanced as far as 13 mm caudal to the lesion	44933
@VP	enhanced as far as 13 mm caudal to the lesion	44937
@VP	Demonstrating that ECs	44984
@VP	used in combination with MP	45054
@VP	solving the spinal cord injury problem	45131
